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A B S T R A C T
Background
Respiratory tract infection with Pseudomonas aeruginosa occurs in most people with cystic fibrosis. Once chronic infection is established,
Pseudomonas aeruginosa is virtually impossible to eradicate and is associated with increased mortality and morbidity. Early infection
may be easier to eradicate.
This is an update of a Cochrane review first published in 2003, and previously updated in 2006 and 2009.
Objectives
To determine whether antibiotic treatment of earlyPseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates
the organism, delays the onset of chronic infection, and results in clinical improvement. To evaluate whether there is evidence that a
particular antibiotic strategy is superior to or more cost-effective than other strategies and to compare the adverse effects of different
antibiotic strategies (including respiratory infection with other micro-organisms).
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from compre-
hensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Most recent search: 08 September 2014.
Selection criteria
We included randomised controlled trials of people with cystic fibrosis, in whom Pseudomonas aeruginosa had recently been isolated
from respiratory secretions. We compared combinations of inhaled, oral or intravenous antibiotics with placebo, usual treatment or
other combinations of inhaled, oral or intravenous antibiotics. We excluded non-randomised trials, cross-over trials, and those utilising
historical controls.
Data collection and analysis
Both authors independently selected trials, assessed risk of bias and extracted data.
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Main results
The search identified 49 trials; seven trials (744 participants) with a duration between 28 days and 27 months were eligible for inclusion.
Three of the trials are over 10 years old and their results may be less applicable today given the changes in standard treatment. Some
of the trials had low numbers of participants and most had relatively short follow-up periods; however, there was generally a low risk
of bias from missing data. In most trials it was difficult to blind participants and clinicians to treatment given the interventions and
comparators used. Two trials were supported by the manufacturers of the antibiotic used.
Evidence from two trials (38 participants) at the two-month time-point showed treatment of early Pseudomonas aeruginosa infection
with inhaled tobramycin results in microbiological eradication of the organism from respiratory secretions more often than placebo,
odds ratio 0.15 (95% confidence interval 0.03 to 0.65) and data from one of these trials, with longer follow up, suggested that this
effect may persist for up to 12 months.
One randomised controlled trial (26 participants) compared oral ciprofloxacin and nebulised colistin versus usual treatment. Results
after two years suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than
no anti-pseudomonal treatment, odds ratio 0.12 (95% confidence interval 0.02 to 0.79).
One trial comparing 28 days to 56 days treatment with nebulised tobramycin solution for inhalation in 88 participants showed that
both treatments were effective and well-tolerated, with no notable additional improvement with longer over shorter duration of therapy.
However, this trial was not powered to detect non-inferiority or equivalence .
A trial of oral ciprofloxacin with inhaled colistin versus nebulised tobramycin solution for inhalation alone (223 participants) failed to
show a difference between the two strategies, although it was underpowered to show this. A further trial of inhaled colistin with oral
ciprofloxacin versus nebulised tobramycin solution for inhalation with oral ciprofloxacin also showed no superiority of the former, with
increased isolation of Stenotrophomonas maltophilia in both groups.
A recent, large trial in 306 children aged between one and 12 years compared cycled nebulised tobramycin solution for inhalation to
culture-based therapy and also ciprofloxacin to placebo. The primary analysis showed no difference in time to pulmonary exacerbation
or proportion of Pseudomonas aeruginosa positive cultures. An analysis performed in this review (not adjusted for age) showed fewer
participants in the cycled therapy group with one or more isolates of Pseudomonas aeruginosa, odds ratio 0.51 (95% CI 0.31 to 0.28).
Authors’ conclusions
We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection
with Pseudomonas aeruginosa. Eradication may be sustained for up to two years. There is insufficient evidence to determine whether
antibiotic strategies for the eradication of early Pseudomonas aeruginosa decrease mortality or morbidity, improve quality of life, or are
associated with adverse effects compared to placebo or standard treatment. Four trials of two active treatments have failed to show
differences in rates of eradication of Pseudomonas aeruginosa.There have been no published randomised controlled trials that investigate
the efficacy of intravenous antibiotics to eradicate Pseudomonas aeruginosa in cystic fibrosis. Overall, there is still insufficient evidence
from this review to state which antibiotic strategy should be used for the eradication of early Pseudomonas aeruginosa infection in cystic
fibrosis.
P L A I N L A N G U A G E S U M M A R Y
Different ways of giving antibiotics to eradicate Pseudomonas aeruginosa infection in people with cystic fibrosis
Review question
We reviewed the evidence for the effectiveness of antibiotics in getting rid of a lung infection with a germ called Pseudomonas aeruginosa
in people with cystic fibrosis.
Background
Cystic fibrosis is an inherited condition where the airways often become blocked with mucus. It is associated with chest infections,
which can lead to progressive breathing failure and death. A germ called Pseudomonas aeruginosa is a frequent cause of infection and is
difficult to treat effectively, once infection has become established.
Search date
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The evidence is current to September 2014.
Study characteristics
We wanted to compare different combinations of inhaled, oral and intravenous (IV) antibiotics for eliminating Pseudomonas aeruginosa
in people with cystic fibrosis and find out if any single treatment works best and is more cost-effective. We included seven trials with a
total of 744 individuals, but the treatments were mostly different so we could not combine the results. Two trials compared tobramycin
to placebo (a dummy treatment). Three trials used a combination of oral ciprofloxacin and inhaled colistin in one group of volunteers
and compared this combination to no treatment in one trial, to inhaled tobramycin in a second trial and to oral ciprofloxacin with
inhaled tobramycin in the third trial. Another trial compared 28 days of inhaled tobramycin to 56 days of inhaled tobramycin and
the final included trial compared regular cycles of inhaled tobramycin (plus oral ciprofloxacin or placebo) to culture-based inhaled
tobramycin (plus oral ciprofloxacin or placebo). Trials included people with cystic fibrosis of both sexes, any age and both mild and
more severe lung disease. The trials lasted from 28 days to 27 months.
Key results
Two small trials (38 volunteers) treating early infection showed that, after two months, nebulised antibiotics were better than no
treatment and eliminated Pseudomonas aeruginosa in most people. One of these trials reported results over a longer period and these
suggested that this effect may last for up to 12 months. Another small trial (26 volunteers) which lasted two years showed that treating
early infection with a combination of nebulised and oral antibiotics was better than no treatment at eliminating Pseudomonas aeruginosa.
A further trial (88 volunteers), which compared 28 days of nebulised tobramycin solution for inhalation to 56 days, showed both
were equally tolerated and effective at eliminating Pseudomonas aeruginosa. Four direct comparisons of oral or inhaled antibiotics (or
combinations of both), one of which reported on 223 volunteers, did not find a difference between different antibiotic combinations. A
recent, large trial in 306 children (aged up to 12 years) compared a regular cycle of treatment to treatment only when it was shown that
a child was infected with Pseudomonas aeruginosa, the treatment used was either an antibiotic or a placebo. When we analysed the data
for this review, we found that when children were given a regular cycle of inhaled tobramycin (with either oral ciprofloxacin or placebo)
fewer of them grew Pseudomonas aeruginosa from their sputum. The official published results from this trial made an adjustment for
age and did not show any difference in the number of times Pseudomonas aeruginosa was grown from samples between the groups, nor
was there any difference in the length of time until the patients had their next chest infection.
Quality of the evidence
Some of the trials were conducted between 10 and 20 years ago and the results may not be applicable to patients today. Some trials
were small and all the trials had quite a short follow-up period. Therefore, we could not show whether treatment made people with
cystic fibrosis feel better or live longer. Given the types of treatment used in most of the trials, it would have been easy for the volunteers
to guess which treatment they were receiving, which might have influenced some of the results. Two trials were supported by the
pharmaceutical industry. Further research is still needed to see whether eliminating the bacteria completely improves the well-being
and quality of life in people with cystic fibrosis and to establish which antibiotic combination provides the best way of eliminating
Pseudomonas aeruginosa.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common life-limiting, autoso-
mal recessively inherited disease in Caucasian populations. Al-
though this is a multisystem disease, the primary cause of death
in CF is respiratory failure resulting from chronic pulmonary in-
fection (FitzSimmons 1993). The most frequent cause of chronic
pulmonary infection beyond infancy in people with CF is Pseu-
domonas aeruginosa (P. aeruginosa) and, once established, appears
to be permanent in the majority of cases (Fitzsimmons 1996). A
number of definitions have been used for chronic P. aeruginosa
infection in CF.
1. The presence of P. aeruginosa in monthly specimens for six
successive months or the development of precipitating antibodies
to P. aeruginosa or both (Valerius 1991).
2. The culture of P. aeruginosa from the sputum or respiratory
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secretions, on two or more occasions extending over six months
or a shorter period if accompanied by a sustained rise of anti-
pseudomonal antibodies (UK CF Trust 2004).
3. The isolation of P. aeruginosa in more than 50% of months
over a 12-month period (Lee 2003) - the second and subsequent
positive specimens in the same month do not count. Conversely,
eradication is defined as all monthly specimens negative for P.
aeruginosa over 12 months.
4. Three or more isolates of P. aeruginosa in a 12-month
period (UK CF Registry 2012).
We have used the first definition in this systematic review.
The age-specific prevalence of P. aeruginosa in pre-school children
is under 5%, rising to 30% at aged 16 years (UK CF Registry
2013). Some authors have suggested that the use of prophylactic
anti-staphylococcal antibiotic therapy in early childhood may pre-
dispose to chronic P. aeruginosa infection (Ratjen 2001b; Stutman
2002). However, this effect was not seen in a systematic review
of prophylactic antibiotic use, including over 400 participants
(Smyth 2012).
In children who are too young to expectorate, cough swabs or
oropharyngeal swabs are the only respiratory specimens which
can be easily obtained. These do not reliably predict the presence
of P. aeruginosa in the lower respiratory tract (Armstrong 1996;
Rosenfeld 1999), whereas flexible fibreoptic bronchoscopy with
bronchoalveolar lavage (BAL) may detect positive P. aeruginosa
in children with negative cough swabs or oropharyngeal swabs
(Douglas 2009; Hilliard 2007). Sputum cultures have been shown
to accurately reflect lower respiratory tract organisms in expecto-
rating children and adults (Iacocca 1963; Thomassen 1984). Over
half of people with CF have chronic infection with P. aeruginosa
by their early twenties (UK CF Registry 2013), although prior to
chronic infectionP. aeruginosa is often isolated intermittently from
respiratory tract specimens. This may represent transient colonies
of P. aeruginosawithin the lower respiratory tract or alternatively it
may reflect the difficulties in accurately detecting P. aeruginosa in
the lungs of youngpeoplewithCF (Burns 2001). The quantity and
type of P. aeruginosa present in the lower respiratory tract changes
as infection becomes established. It is known that P. aeruginosa
has two major phenotypes - mucoid and non-mucoid. Following
first isolation there is a progressive increase in the density of P.
aeruginosa colonies in the lower respiratory tract (Rosenfeld 2001).
Initial isolates often show a non-mucoid phenotype; however, as
infection progresses a mucoid phenotype may prevail and will be
more difficult to eradicate. Douglas has reported a relatively high
prevalence (18.2%) of mucoid P. aeruginosa) at first isolation in
newborn screened infants, speculating that the notion of transfor-
mation from non-mucoid to mucoid phenotype under environ-
mental pressure may be inaccurate in young children. (Douglas
2009). It has been reported that P. aeruginosa provokes an inflam-
matory response of the lower respiratory tract (Muhlebach 1999)
and there is a marked step up in this inflammatory response as the
number of P. aeruginosa colonies increases (Armstrong 1996).
The presence of P. aeruginosa in respiratory secretions is a major
predictor of mortality in children with CF (Emerson 2002). Indi-
viduals with CF infected with P. aeruginosa also suffer greater mor-
bidity with a more rapid deterioration in lung function (Emerson
2002; Pamukcu 1995) and a more rapid decline in chest radio-
graph score (Kosorok 2001), poor growth, reduced quality of life,
increased hospitalisation and increased need for antibiotic treat-
ment (Ballman 1998; Nixon 2001; Winnie 1991). Some stud-
ies suggest there is a temporal relationship between the onset of
chronic infection and increased morbidity (Abman 1991;Hudson
1993; Kosorok 2001; Parad 1999), whilst others do not support
these findings (Kerem 1990; Rosenfeld 2001). On balance, there
seems to be good evidence from well-designed non-experimen-
tal studies that clinical state deteriorates after first isolation of P.
aeruginosa.
Description of the intervention
Several strategies exist to treat early infectionwithP. aeruginosa and
include the use of the inhaled antibiotics such as colistin and to-
bramycin (Littlewood 1985; Ratjen 2001a), oral quinolones such
as ciprofloxacin (Taccetti 2005) and intravenous antibiotics usu-
ally consisting of combination of an aminoglycoside with a beta-
lactam (Döring 2000; Douglas 2009).
How the intervention might work
As well as antibiotic treatment of P. aeruginosa given at the time
of first isolation, other strategies have the potential to prevent or
delay infection of the respiratory tract. These include avoidance of
contact with people who carry P. aeruginosa (UK CF Trust 2004)
and the development of vaccines against P. aeruginosa (Johansen
2013). Uncontrolled series have indicated that a variety of anti-
pseudomonal antibiotics either singly (Littlewood 1985; Ratjen
2001a) or in combination (Vazquez 1993) at first isolation may
delay the onset of chronic infection. A trial using historical con-
trols suggested that oral ciprofloxacin and nebulised colistin are
effective in delaying or preventing chronic infection (Frederiksen
1997). An uncontrolled pilot study of intravenous therapy sug-
gested that intravenous treatment alone was less effective in delay-
ing the onset of chronic infection (Steinkamp 1989). There is also
evidence supporting eradication therapy from long-term observa-
tional studies of chronic infection with P. aeruginosa in CF clinics
such as the study reported by Lee (Lee 2004).
Why it is important to do this review
There are differences in the approach to detection and manage-
ment of first isolation of P. aeruginosa. Some CF centres advocate
frequent microbiological surveillance with attempts to eradicate P.
aeruginosawhen it first appears in the lung (Döring 2000), whereas
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others treat only when clinical or radiological signs of pulmonary
infection are present (Ramsey 1996). There is evidence that, when
P. aeruginosa is cleared from respiratory secretions it is not simply
suppressed because, when infection recurs, this is with a geneti-
cally distinct organism inmost cases (Munck 2001). Evidence that
eradication strategies result in increased survival or improved qual-
ity of life for people with CF are from observational studies alone.
There are multiple different eradication regimens that have been
described using different anti-pseudomonal antibiotics in differ-
ent combinations of intravenous, oral or nebulised (or both) and
with varying doses and duration of therapy (Lee 2009). Given the
expense of chronic anti-pseudomonal suppressive therapy, there
is a clear rationale for early eradication from a cost-effectiveness
perspective and this is supported by observational data (Taccetti
2005); however, there has not been any formal evaluation of cost
effectiveness to date.
This is an update of a Cochrane review first published in 2003,
and previously updated in 2006 and 2009 (Langton Hewer 2009;
Wood 2003; Wood 2006).
O B J E C T I V E S
To determine whether antibiotic treatment of early P. aeruginosa
infection in children and adults with CF alters clinical and micro-
biological outcome when compared to usual treatment.
To test the hypotheses that antibiotics against P. aeruginosa, given
at the time of first isolation, reduce CF-related mortality; improve
quality of life; improve pulmonary function; nutritional status; and
reduce the need for subsequent hospitalisation and consumption
of antibiotics.
To investigate whether these antibiotics prevent or delay the onset
of chronic infection of the respiratory tract with P. aeruginosa;
increase the incidence of isolates of other micro-organisms from
the respiratory tract; and are associated with adverse effects which
are either important to the individual with CF or have long-term
sequelae.
To investigate whether there is evidence of superior P. aeruginosa
eradication efficacy or improved cost-effectiveness between differ-
ent antibiotic strategies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Children and adults with CF, diagnosed clinically and by sweat or
genetic testing (or both) with a first ever positive microbiological
isolate of P. aeruginosa from a respiratory tract specimen. Trials will
also be included where the participants have been proven to be free
of P. aeruginosa for at least six months before a new isolation and
should not be currently receiving Pseudomonas-suppressing treat-
ment such as daily inhaled antibiotic therapy. Participants should
be enrolled into a trial within six months (post hoc change - previ-
ously not more than two months) from isolation of P. aeruginosa.
In a further post hoc change, we have also altered our eligibility cri-
teria to allow trials where all participants receive some eradication
therapy before randomisation (see Differences between protocol
and review). People with CF of all ages and disease severity will be
included.
Types of interventions
Combinations of inhaled, oral or intravenous antibiotics with the
aim of eradicating first pulmonary isolates of P. aeruginosa com-
pared with placebo or usual treatment (or both) or other combi-
nations of inhaled, oral or intravenous antibiotics.
Types of outcome measures
Primary outcomes
1. Eradication of P. aeruginosa from the respiratory tract as
defined by
i) clearance of P. aeruginosa from bronchoalveolar lavage
(BAL), sputum or oropharyngeal cultures at 1, 2, 3, 6, 12 and 24
months after commencement of therapy
ii) time to next isolation of P. aeruginosa from BAL,
sputum or oropharyngeal cultures
Secondary outcomes
1. Mortality
2. Quality of life assessment
3. Spirometric lung function (e.g. forced expiratory volume in
one second (FEV1) and forced vital capacity (FVC)) expressed as
percentage predicted values for age, sex and height
4. Growth and nutritional status as measured by weight,
height (children), body mass index (BMI) or z score
5. Frequency of respiratory exacerbations as defined by:
i) frequency of infective pulmonary exacerbations
expressed as the number of exacerbations per patient year
ii) time to next course of IV antibiotics from
commencement of therapy
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iii) days in hospital expressed as days in hospital per
patient year
iv) days of antibiotic usage expressed as days of antibiotic
usage per patient year
6. Isolation of other micro-organisms from the respiratory
tract expressed as the number of positive cultures per patient year
(where available, the microbiology detection method will be
described in view of the differences in sensitivity and specificity
of oropharyngeal, sputum and BAL samples for bacteriology,
mycology and non-tuberculous mycobacteria)
7. Adverse effects to antibiotics, e.g. renal or auditory
impairment and hypersensitivity reactions
Additional outcomes which have arisen during the review
1. Time to chronic infection (as defined above in Description
of the condition)
2. Clinical and radiological scores
3. Cost effectiveness (trials looking at cost effectiveness will be
compared, where possible)
Search methods for identification of studies
Relevant trials were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: antibiotics AND (pseudomonas
aeruginosa OR mixed infections) AND (eradication OR un-
known).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of Embase to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching the abstract books of three major CF con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the Trials Register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s trials register: 08
September 2014.
We have also searched the relevant clinical trials databases
clinicaltrials.gov/ and ISRCTN. We used the search terms “cystic
fibrosis” AND “Pseudomonas aeruginosa” AND “eradication”.
Date of last search: 01 September 2014.
Data collection and analysis
Selection of studies
For the original review, two authors (DW, AS) independently se-
lected the trials to be included in the review. From Issue 3, 2009
of The Cochrane Library two authors (SLH, AS) selected the trials
to be included in the review. Where there was disagreement on
the suitability of a trial for inclusion in the review, or on its risk of
bias, the authors reached a consensus by discussion.
Data extraction and management
Each author independently extracted data using standard data ac-
quisition forms. Where there was disagreement on the suitability
of a trial for inclusion in the review, or on its risk of bias, the
authors reached a consensus by discussion.
We planned to group outcome data into those measured at one,
three, six, twelve months and annually thereafter. In addition, we
previously stated that if outcome data were recorded at other time
periods as well, that we would also consider examining these data.
Some trials reported data at two months for some outcomes and
we have included these data within the review. In the Taccetti trial,
cumulative data were reported at six months and final follow-up
data at a median of 16 months (range 12 to 28 months); we have
included both time points in our analysis (Taccetti 2012). In the
Treggiari trial, cumulative data for pulmonary exacerbations and
isolates of P. aeruginosa are presented for the 70-week follow-up
period and these have been reported and analysed in this review
(Treggiari 2011).
Assessment of risk of bias in included studies
For earlier versions of this review, in order to assess the risk of bias,
each author independently assessed the methodological quality
of each trial, based on the method described by Schulz (Schulz
1995). From the 2011 update, each author independently assessed
the risk of bias using the tool recommended by the Cochrane
Collaboration (Higgins 2011). The risk of bias was judged to be
high, unclear or low for the domains of:
• sequence generation;
• allocation concealment;
• blinding (risk of bias increased as the level of blinding
decreased);
• incomplete outcome data (the risk of bias increased if any
withdrawals were not adequately described and reasons for
withdrawals given, or if the withdrawals were not equal across
groups);
• selective outcome reporting (bias increased if stated
outcome measures were only partially reported or not reported at
all);
• other potential sources of bias.
Where there was disagreement on the quality and risk of bias of a
trial, the authors reached a consensus by discussion.
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Measures of treatment effect
For binary outcome measures, in order to allow an intention-to-
treat analysis, the authors sought data on the number of partici-
pants with each outcome event, by allocated treated group, irre-
spective of compliance andwhether or not the participant was later
thought to be ineligible or otherwise excluded from treatment or
follow up. We calculated a pooled estimate of the treatment effect
for each outcome across trials - the odds ratio (OR) or the ratio of
the odds of an outcome among treatment allocated participants
to the corresponding odds among controls with 95% confidence
intervals (CIs).
For continuous outcomes, in order to allow an intention-to-treat
analysis, we sought outcome data by allocated treated group, ir-
respective of compliance and whether or not the participant was
later thought to be ineligible or otherwise excluded from treat-
ment or follow up.We recorded either mean change from baseline
for each group or mean post-treatment or intervention values and
standard deviation (SD). We calculated a pooled estimate of treat-
ment effect by calculating the mean difference (MD) with 95%
CIs.
The authors have reported longitudinal data as individual time
points. We realise that this method ignores any correlation be-
tween the participants; however, we have been unable to analyse
these data using more appropriate methods as we do not have the
correlation co-efficient for these data. If in the future, we are able
to obtain the correlation co-efficient, we will analyse these data
more appropriately.
In this version of the review, we entered time-to-event data into
the meta-analysis using the log hazard ratio. This was possible for
the outcome ’time to pulmonary exacerbation’ (severe or any), in
the comparison of cycled versus. culture-based therapy (Analysis
6.5; Analysis 6.7) and ciprofloxacin versus placebo (Analysis 7.5;
Analysis 7.7). We presented binary data on clearance of P. aerugi-
nosa from BAL, sputum or oropharyngeal cultures and occurrence
of chronic infection with P. aeruginosa at multiple time points. We
calculated the OR at each time point separately, thus ignoring the
correlation between time points. For future updates of this review,
for time-to-event data, such as time to next P. aeruginosa infection
or time to chronic infection, the authors will attempt to obtain
individual patient data (IPD). We will use these IPD to provide
estimates of the log hazard ratio and its standard error and plan
to combine time-to-event data from trials in a meta-analysis. We
used the generic inverse variance (GIV) to analyse the data for
time to next isolation of P. aeruginosa from the Ratjen trial (Ratjen
2010).
Unit of analysis issues
Cross-over trials are not eligible for inclusion within this review.
The natural history of infection with P. aeruginosa in CF com-
prises an initial infection with the organism usually in planktonic
form, followed by chronic infection (in which the P. aeruginosa
frequently exists in the mucoid state). In the planktonic form, an-
tibiotics can eradicate the organism; however, persistent infection
is associated with biofilm growth and adaptive evolution medi-
ated by genetic variation. The development of mucoidy, hyper-
mutability and the acquisition of mutational antibiotic resistance
are important factors associated with persistent infection and are
associated with increased difficulty in eradication (Ciofu 2012).
In a cross-over trial comparing active treatmentwith placebo, given
the progression of infections due to of P.aeruginosa, the group re-
ceiving the active treatment after placebo will be at a disadvan-
tage compared with those receiving active treatment first. TheP.
aeruginosa may form a biofilm during placebo treatment and so
it would not be able to be eradicated during the active treatment
phase. Hence, a cross-over trial is an inappropriate design and the
authors have not included cross-over trials in this review.
Dealing with missing data
In trials where outcome data were unavailable for randomised
participants, the authors performed an available-case analysis. This
available-case analysis included data on only those participants
whose results are known, using as a denominator the total number
of people who completed the trial for the particular outcome in
question.
When data were incomplete, the authors imputed themissing data
to provide best-case and worst-case scenarios, in order to show the
range of possible results for the combined analysis (see Analysis
1.4; Analysis 1.5). The best-case scenario analysis is based on the
assumption that all the missing data points represented beneficial
clinical outcomes, whereas the worst-case analysis assumes that all
missing data points had a negative clinical outcome.
Assessment of heterogeneity
For future updates of this review, if we are able to combine a suf-
ficient number of trials (at least four), we will test for heterogene-
ity using the I2 statistic (Higgins 2003). We will consider values
of I2 up to 30% to indicate little or no heterogeneity, values be-
tween 30% and 60% to represent moderate heterogeneity, values
from 60% to 90% to represent substantial heterogeneity and val-
ues over 90% to represent considerable heterogeneity. We accept
that the importance of the observed value of I2 depends firstly on
the magnitude and direction of effects and secondly on strength
of evidence for heterogeneity (e.g. P value from the Chi2 test, or a
confidence interval for I2). In a future version of this review (with
more trials included in the meta-analysis of individual treatment
comparisons), if we find evidence of at least substantial clinical
heterogeneity (as defined above) in the included trials, we will per-
form a random-effects analysis.
Assessment of reporting biases
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The authors sought evidence of reporting bias by comparison of
the reported outcomes with those listed in the trial’s methodolog-
ical description. Where important outcomes have not been iden-
tified, we have requested the original trial protocol from the au-
thors.
Data synthesis
The authors have analysed the data using a fixed-effect model.
If, in future updates of this review, we find evidence of at least
substantial clinical heterogeneity (as defined above) in the included
trials, we plan to perform a random-effects analysis.
Subgroup analysis and investigation of heterogeneity
If we identify a moderate degree of heterogeneity or higher
(Higgins 2003) and are able to combine a sufficient number of
trials (at least 10), thenwe will investigate this with subgroup anal-
yses. We plan to categorise participants if possible as P. aeruginosa-
free and P. aeruginosa-naive according to the definition by Lee (Lee
2003). These subgroups will be analysed separately.
Sensitivity analysis
We also plan to test the robustness of our results with the following
sensitivity analyses:
• trials where participants receive treatment within three
months of isolation of P. aeruginosa versus those where the
interval is between three and 12 months;
• trials with high risk of bias versus low risk of bias for
generation of allocation sequence;
• trials with a high risk of bias versus a low risk of bias for
concealment of allocation;
• multi-centre versus single centre trials.
R E S U L T S
Description of studies
Results of the search
Our search identified a total of 49 trials, none of these were cross-
over trials. Of these 49 trials, seven met our inclusion criteria
(Gibson 2003; Proesmans 2013; Ratjen 2010; Taccetti 2012;
Treggiari 2011; Valerius 1991; Wiesemann 1998); we identified
one trial which is still ongoing and will include data from this trial
in a future update of this review once they have been published
(TORPEDO Trial); 40 trials were excluded and one trial is listed
as ’Awaiting classification’ (Noah 2010). We have contacted the
investigators of this trial for further information to allow us to
include or exclude it at a future update.
Included studies
The seven included trials enrolled a total of 744 participants
(Gibson 2003; Proesmans 2013; Ratjen 2010; Taccetti 2012;
Treggiari 2011; Valerius 1991; Wiesemann 1998).
Trial characteristics
All seven included trials were randomised controlled trials of par-
allel design. Two trials were placebo-controlled (Gibson 2003;
Wiesemann 1998); one trial compared active treatment tono treat-
ment (Valerius 1991); and three trials were open-label trials com-
paring different active treatments (Proesmans 2013; Ratjen 2010;
Taccetti 2012). The design of the Treggiari trial was complex, with
randomisation to cycled treatment with tobramycin solution for
inhalation (TSI) or culture-based treatment and further randomi-
sation to additional oral ciprofloxacin or placebo (Treggiari 2011).
One trial reported stratification for age and participating centre
(Gibson 2003), another trial reported stratification by age and
FEV1 values as an expression of illness severity (Taccetti 2012);
the remaining five trials did not use stratification (Proesmans
2013; Ratjen 2010; Treggiari 2011; Valerius 1991; Wiesemann
1998). Two trials stated that theywere double-blind (Gibson 2003;
Wiesemann 1998); the Treggiari trial used placebo to blind for
ciprofloxacin but not for TSI (Treggiari 2011); the other trials
could not be blinded due to differing treatment regimens. Five
trials were multicentre (Gibson 2003; Ratjen 2010; Taccetti 2012;
Treggiari 2011; Wiesemann 1998) and the other two were single-
centre trials (Proesmans 2013; Valerius 1991). Five trials were
based in Europe (Proesmans 2013; Ratjen 2010; Taccetti 2012;
Valerius 1991; Wiesemann 1998) and two in North America (
Gibson 2003; Treggiari 2011). The number of participants in
each trial ranged from 21 to 306 and were as follows: 306 in the
Treggiari trial (Treggiari 2011); 223 in the Taccetti trial (Taccetti
2012); 88 in the Ratjen trial (Ratjen 2010); 26 in the Proesmans
trial (Proesmans 2013); 26 in the Valerius trial (Valerius 1991);
22 in the Wiesemann trial (Wiesemann 1998); and 21 in the
Gibson trial (Gibson 2003). The Gibson trial reported that the
planned sample size was 98 participants, but randomisation was
stopped after an early interim analysis by the Data Monitoring
Committee was undertaken due to poor accrual. This analysis
showed a statistically significant treatment effect and so the trial
was stopped (Gibson 2003). The duration of the trials varied and
ranged from 28 days (Gibson 2003) to 27months (Valerius 1991).
Participant characteristics
All seven trials had approximately equal numbers of males and
females. Only two trials recruited adult participants; Taccetti re-
cruited participants aged from 1 to 35 years (Taccetti 2012) and
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in the Ratjen trial any patient over six months of age was eligible
for inclusion (Ratjen 2010). Two trials were restricted to younger
children: six months to six years (Gibson 2003) and 1 to 12 years
(Treggiari 2011). All seven trials specified that participants had to
have microbiological evidence of recent onset of airway infection
with P. aeruginosa. However, the interval allowed between isola-
tion of P. aeruginosa and randomisation to study treatment var-
ied greatly, from four weeks (Proesmans 2013; Wiesemann 1998)
to as long as six months (Treggiari 2011). Two trials additionally
specified that individuals with raised titres to anti-pseudomonal
antibodies were excluded from the trial (Ratjen 2010; Wiesemann
1998). Other data from the EPIC study have shown that raised
antibodies to P. aeruginosa (anti-alkaline protease and anti-exo-
toxin A) are associated with an increased risk of recurrence in the
60 weeks following eradication treatment (Anstead 2013). Studies
excluding participants with raised antibodies might therefore be
expected to achieve higher eradication rates.
Intervention
Trials have used various combinations of inhaled tobramycin, in-
haled colistin, oral ciprofloxacin, placebo and no treatment. The
duration of the intervention has varied greatly, from three weeks
(Valerius 1991) to one year (Wiesemann 1998). Two trials com-
pared tobramycin to placebo (Gibson 2003; Wiesemann 1998).
One trial used tobramycin solution for inhalation (TSI) TOBI®
(nowmarketed by Novartis) at a dose of 300 mg twice-daily for 28
days (Gibson 2003); the second trial used aerosolised tobramycin
parenteral preparation (Eli Lilly, Bad Homburg, Germany) at a
dose of 80 mg twice-daily for 12 months (Wiesemann 1998). Rat-
jen evaluated a short (28 days) versus a longer (56 days) TSI course
(Ratjen 2010). Participants in the Treggiari trial were randomised
to receive either cycles of four weeks of treatment with nebulised
TSI in every 12-week period or TSI only when respiratory culture
was positive for P. aeruginosa (Treggiari 2011). In this trial, partic-
ipants were also randomised to receive either oral ciprofloxacin or
placebo for two weeks, commencing at the same time as TSI. This
design resulted in a four-arm trial where all trial participants had
an initial 28-day course of TSI, with an additional 28 days given if
the patient remained positive after initial treatment. Ciprofloxacin
or placebo was not given with second course of TSI and follow
up was for 18 months from randomisation and first treatment
with TSI (Treggiari 2011). Three trials evaluated inhaled colistin
in combination with oral ciprofloxacin (Proesmans 2013; Taccetti
2012;Valerius 1991). Proesmans compared colistin 2millionunits
(MU) twice daily for three months (in combination with oral ci-
profloxacin 30 mg/kg/day) to TSI 300 mg twice daily for 28 days
(Proesmans 2013). The Taccetti trial compared 28 days of inhaled
colistin with 28 days TSI; both arms also had oral ciprofloxacin 30
mg/kg/day for 28 days (Taccetti 2012). Valerius compared colistin
1 MU (plus ciprofloxacin 250 mg to 750 mg), both given twice
daily for three weeks, for initial and any subsequent isolate of P.
aeruginosa to no treatment (Valerius 1991).
Outcome measures
The most widely used primary outcome measure was eradication
of P. aeruginosa from respiratory secretions, though definitions of
eradication differ considerably between trials. In the Gibson trial,
the primary outcome was the change in P. aeruginosa density, on
BAL, from baseline to 28 days (Gibson 2003). However, the trial
also looked at eradication, defined as a density of P. aeruginosa
in BAL of less than 20 colony forming units (CFU) at 28 days
from baseline. Proesmans defined eradication as a negative culture
result for P. aeruginosa (from sputum, cough swab or BAL) at 28
days or three months (depending on which intervention the par-
ticipant received) (Proesmans 2013). Both trials based successful
eradication on a single specimen (Gibson 2003; Proesmans 2013).
In contrast, Taccetti used a more stringent definition of eradica-
tion as per guidance published by the UK CF Trust of three neg-
ative cultures in a six-month period (Taccetti 2012; UK CF Trust
2004). Ratjenused themedian time to recurrence of any strain ofP.
aeruginosa during a 27-month follow-up period (Ratjen 2010). In
the oldest trial, the primary outcome measure was time to chronic
infection with P. aeruginosa, defined as the presence of P. aerugi-
nosa in monthly sputum samples for six consecutive months or the
development of precipitating serum antibodies against P. aerugi-
nosa or both (seeDescription of the condition for other definitions
of chronic infection) (Valerius 1991). There were two primary
outcomes in the Treggiari trial, time to pulmonary exacerbation
requiring intravenous antibiotics and proportion of P. aeruginosa
positive cultures over the 18-month trial period (Treggiari 2011).
Other measured outcomes included less severe pulmonary exac-
erbations, Pseudomonas antibody levels, lung function, nutritional
status, modified Shwachman score and monitoring for adverse
clinical and microbiological effects.
Excluded studies
We excluded 40 trials from our analysis for a number of reasons.
Three trials were excluded because therapy was not randomised
(Gibson 2007; Postnikov 2000; Schelstraete 2010) and one trial
was excluded because it was an observational study (Ballman
1998). Four trials were excluded as they did not have a control
group (Heinzl 2002; Littlewood 1985; Ratjen 2001a; Steinkamp
1989) and a further five because they used a historical control
group (Frederiksen 1997; Griese 2002; Kenny 2009; Taccetti
2005; Vazquez 1993). A total of 16 trials were excluded as they
involved participants with chronic P. aeruginosa infection (Clancy
2013; Coates 2011; Goss 2009; Konstan 2010; Latzin 2008;
Lenoir 2007; Mazurek 2012; Oermann 2009; Postnikov 2007;
Prayle 2013; Ramsey 1999; Retsch-Bogart 2008; Retsch-Bogart
2009; Steinkamp 2007; Trapnell 2012; Wainwright 2011b). Two
trials were excluded as they were designed to evaluate a diagnostic
technique forP. aeruginosa (Brett 1992;Wainwright 2011a). A fur-
ther two trials were excluded as they evaluated symptomatic rather
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than eradication treatment (Church 1997; Schaad 1997) and one
was of a prophylactic antibiotic regimen to prevent infection with
P. aeruginosa (Tramper-Stranders 2009). Five trials looked at phar-
macokinetics and drug tolerability (Alothman 2002; Alothman
2005; Geller 2007; Rietschel 2009; Schuster 2013) and the final
trial was excluded as it looked at antibiotic sinonasal nebulisation
aiming to eradicate from the sinuses only (Mainz 2014).
Risk of bias in included studies
Please see further information in the risk of bias sections of the
tables (Characteristics of included studies) and the graphical risk
of bias summary (Figure 1).
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All seven trials were described as randomised controlled trials; in
four, the method of generation of allocation sequence was not
stated; hence the trials are judged to have an unclear risk of bias
(Gibson 2003; Proesmans 2013; Ratjen 2010; Valerius 1991).
The remaining three trials are judged to have a low risk of bias
(Taccetti 2012; Treggiari 2011; Wiesemann 1998). In the first of
these, Taccetti describes a balanced randomisation sequence that
was created using statistical software using permuted blocks of
size 10 (Taccetti 2012). Treggiari employed a computer random
number generator to assign treatments within permuted blocks
of 12 (Treggiari 2011). In the Wiesemann trial, the allocation
sequencewas generated using a coinflip (Wiesemann 1998). There
is no information as to who was responsible for the coin flip or
what controls were in place to ensure validity of the result of the
coin flip; however we have still judged this to have a low risk of
bias.
In five trials it was not reported how allocation was concealed and
we judged these to have an unclear risk of bias (Gibson 2003;
Proesmans 2013; Ratjen 2010; Valerius 1991; Wiesemann 1998).
In the Taccetti trial, the staff involved in randomisation and in
treatment assignments were “kept separate” and we judged this
trial to have a low risk of selection bias (Taccetti 2012). In the
Treggiari trial, randomisation was remote and so allocation was
concealed (Treggiari 2011).
Blinding
Two trials were reported as double-blind trials (Gibson 2003;
Wiesemann 1998). Gibson did not provide any details in the pub-
lished paper regarding who was blinded or the method of blind-
ing (Gibson 2003). However, in response to a request for further
information, Dr Gibson confirmed that drugs and placebo were
sufficiently masked that neither participants or clinicians were able
to differentiate between them. Wiesemann reported that partici-
pants were blinded by providing a placebo inhalation with a simi-
lar taste to the treatment inhalation, but it is not clear whether the
clinicians administering the treatment were blinded to treatment
allocation; however, we still judged this to have a low risk of bias
(Wiesemann 1998).
In the Treggiari trial, the oral ciprofloxacin treatment was blinded
but the TSIwas open label and sowe judged this to have an unclear
risk of bias (Treggiari 2011).
The remaining four trials did not utilise blinding and were judged
to have a high risk of bias (Proesmans 2013; Ratjen 2010; Taccetti
2012; Valerius 1991). The Proesmans trial compared an inhaled
intervention to a combination of inhaled and oral treatment, so
blinding of participants and clinicians was not possible; there is
no information available as to whether the outcome assessors were
blinded (Proesmans 2013). The Ratjen trial was open label com-
paring 28 or 56 days of nebulised therapy and made no attempt
at blinding (Ratjen 2010). The Taccetti trial was also open label
comparing 28 days of inhaled colistin with 28 days of TSI, both
groups also receiving 28 days of oral ciprofloxacin (Taccetti 2012).
Valerius compared a combination of inhaled and oral treatment
to no treatment, so again blinding of participants and clinicians
was not possible and no information is available with regards to
the outcome assessors (Valerius 1991).
Incomplete outcome data
Six trials were judged to have a low risk of bias (Gibson 2003;
Proesmans 2013; Ratjen 2010; Taccetti 2012; Treggiari 2011;
Valerius 1991). Four trials were analysed on an intention-to-treat
basis; all four reported data on all participants who were ran-
domised (Gibson 2003; Proesmans 2013; Taccetti 2012; Valerius
1991). In the Ratjen trial, 65 of the 88 randomised participants
were included in the primary outcome (time to recurrence of P.
aeruginosa). A total of 52 participants were prematurely withdrawn
from the trial, but these were approximately evenly distributed
across the two treatment groups and reasons were given for each
withdrawal; we therefore judge there to be a low risk of bias (Ratjen
2010). In the Treggiari trial only two of 306 randomised partic-
ipants were excluded from the analysis (because they did not re-
ceive treatment) (Treggiari 2011).
One trial had an unclear risk of bias (Wiesemann 1998). Five par-
ticipants withdrew from this trial after randomisation and only
baseline data at entry to the trial were presented for these partici-
pants; to date we have been unable to obtain further outcome data.
The trial was therefore analysed on an available-case basis and we
judged it to have an unclear risk of bias (Wiesemann 1998).
Selective reporting
It is current practice for newer trials to publish a protocol, but we
have not been able to locate a published protocol for the Taccetti
trial and have therefore judged this trial to have an unclear risk of
bias (Taccetti 2012).
We judged three trials to have a high risk of bias (Proesmans
2013; Ratjen 2010; Wiesemann 1998). Although a protocol for
the Proesmans trial was available online and we were able to con-
firm from the full paper that all outcomes from the protocol
were measured, the paper did not provide actual data for BMI
z score, weight z score or frequency of exacerbations and simply
reported that none of these changed significantly for trial par-
ticipants (Proesmans 2013). Ratjen reported that there were no
major short-term (at three months) or long-term (at 27 months)
changes in spirometry, but did not record the figures for either
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of the two groups. In addition, only summary statements and no
numerical data were provided for weight, height or BMI (Ratjen
2010). Wiesemann reported no change in spirometric pulmonary
function during or after the treatment period, but again no data
were given (Wiesemann 1998).
We judged three trials to have a low risk of bias from selective
reporting (Gibson 2003; Treggiari 2011; Valerius 1991). The trial
protocol for the EPIC trial was published as a separate paper;
primary and secondary outcome measures were clearly described
in the protocol and data on all of these outcomes were presented in
either the main paper, related papers or in the online supplement
(Treggiari 2011). We have compared the ’Methods’ sections of
the reports from the remaining trials with the ’Results’ sections of
the same and have not found any evidence of selective reporting
(Gibson 2003; Valerius 1991).
Other potential sources of bias
We judged one trial to have a high risk due to other potential
sources of bias (Gibson 2003). The Gibson trial planned to recruit
to a sample size of 98 participants, but was stopped early by the
Data Monitoring Committee after interim analysis of the first 21
participants showed a statistically significantmicrobiological effect
in favour of the tobramycin-treated group (Gibson 2003). This
trial was supported in part by Chiron, the manufacturer of the
inhaled tobramycin (Gibson 2003).
We judged the Ratjen trial to have an unclear risk due to other po-
tential sources of bias (Ratjen 2010). This trial recruited fewer par-
ticipants than planned, the total number of planned randomised
participants was 100, but 35 from the recruited cohort of 123
were not randomised: 31 because of high P. aeruginosa antibody
levels (which led the investigators to believe that they were chron-
ically infected with P aeruginosa); one for an adverse event; one
where consent was withdrawn; one for a protocol deviation; and
one ’other’ (unspecified) reason (Ratjen 2010). Therefore the trial
investigators actually randomised 88 participants and the primary
outcome was evaluable in 65 of these (Ratjen 2010). The trial re-
sults cannot be generalised to a populationwhere anti-Pseudomonas
antibodies are not measured. Furthermore, like the earlier Gibson
trial, this trial was initially supported by Chiron and later Novartis
Pharma, the manufacturer of TSI (Ratjen 2010).
The Proesmans study was judged to have an unclear risk of bias in
view of the different time-points at which the primary outcome
was measured - at 28 days in the inhaled tobramycin group and
three months in the colistin with ciprofloxacin group (Proesmans
2013).
In four trials no other potential source of bias was identified and
thesewere judged tohave a low risk of bias (Taccetti 2012;Treggiari
2011; Valerius 1991; Wiesemann 1998).
Effects of interventions
Inhaled tobramycin versus placebo
This comparison included two trials with 43 participants (Gibson
2003; Wiesemann 1998).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
The intervention (inhaled tobramycin) was given in a very differ-
ent dose in the Wiesemann trial (80 mg twice daily) compared to
the Gibson trial (300 mg twice daily) (Gibson 2003; Wiesemann
1998). In the Gibson trial, significantly fewer children who re-
ceived TSI had a positive BAL at one month, OR 0.01 (95% CI
0.00 to 0.30), but not at two months, OR 0.21 (95% CI 0.03 to
1.47) (Analysis 1.1). Results were not available for all the partici-
pants in theWiesemann trial, thereby precluding an intention-to-
treat analysis (Wiesemann 1998).Wiesemann was able to demon-
strate a statistically significant reduction in the odds of a positive
culture from the respiratory tract specimen only after six months,
OR 0.06 (95% CI 0.00 to 0.92) and 12 months of treatment, OR
0.02 (95% CI 0.00 to 0.67) but not at one, two or three months
(Analysis 1.2). An available-case analysis of the data presented in
the Wiesemann trial showed that, when combined with the data
from the Gibson trial, there was a reduction in the odds of a posi-
tive culture in the treatment group compared to the placebo group
at one month, OR 0.06 (95% CI 0.01 to 0.33); and two months,
OR 0.15 (95% CI 0.03 to 0.65) both of which were statistically
significant (Analysis 1.3).
A sensitivity analysis following imputation of the missing data
to provide best-case and worst case-scenarios for the combined
analysis showed a range of possible results. The best-case scenario
showed a reduction in the odds of a positive culture of P. aeruginosa
in the treatment group at both one month, OR 0.06 (95% CI
0.01 to 0.30); and two months, OR 0.14 (95% CI 0.03 to 0.60)
(Analysis 1.4). Furthermore, these imputed data also showed a
significant difference in favour of tobramycin at six months, OR
0.04 (95% CI 0.00 to 0.48) and 12 months, OR 0.01 (95% CI
0.00 to 0.26), but not at threemonths (Analysis 1.4). In the worst-
case scenario the odds of a positive culture was reduced at one
month, OR 0.08 (95% CI 0.02 to 0.38) and two months, OR
0.18 (95% CI 0.04 to 0.73), but was not statistically significant
for Wiesemann alone at three, six or 12 months (Analysis 1.5).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
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Neither trial assessed or reported on this outcome.
Secondary Outcomes
1. Mortality
Mortality was not included as an outcome in either trial, but there
were no reported deaths during any of the trial periods (Gibson
2003; Wiesemann 1998).
2. Quality of life
Neither trial assessed or reported on this outcome.
3. Spirometric lung function
Wiesemann reported no change in spirometric pulmonary func-
tion during or after the treatment period, but no data were given
(Wiesemann 1998). Gibson did not assess or report on spiromet-
ric lung function; most of the participants in this trial were too
young to perform spirometry reliably (Gibson 2003).
4. Growth and nutritional status
Only the trial by Gibson presented data on weight (Gibson 2003).
There was no significant difference found between the two groups
in the change in weight from baseline (measured at trial entry)
and subsequent weights measured at one month and two months
(Analysis 1.6).
5. Frequency of respiratory exacerbations
Neither trial assessed or reported on this outcome.
6. Isolation of other micro-organisms
Gibson reported no changes in the prevalence of other micro-or-
ganisms, including multi-resistant organisms, cultured from respi-
ratory secretions (Gibson 2003). Wiesemann did not collect data
on this outcome (Wiesemann 1998).
7. Adverse effects of antibiotics
Gibson reported cough in association with inhalation in seven out
of eight participants in the treatment group and in 12 out of 13 in
the placebo group, but this result was not statistically significant
(Analysis 1.7) . There was no evidence of a difference in serum
creatinine levels or auditory threshold between the groups, how-
ever the numbers of participants was small (Gibson 2003). Wiese-
mann reported one withdrawal from the placebo group because
of cough, however the authors did not report on the presence or
absence of cough in other participants (Wiesemann 1998).
Additional outcomes which have arisen during the review
1. Time to chronic infection
Neither trial assessed or reported on this outcome.
2. Clinical and radiological scores
Only the Gibson trial reported modified Shwachmann scores,
which were recorded at one month and two months from enrol-
ment and were expressed as both mean scores with SDs and mean
change from baseline with SDs (Gibson 2003). There were no
significant differences between the two groups in changes in ei-
ther mean scores or modified Schwachman scores from baseline
at either one month or two months (Analysis 1.8).
3. Cost
Neither trial reported a health economic analysis.
Oral ciprofloxacin and inhaled colistin versus no
treatment
This intervention included only one trial with 26 participants
(Valerius 1991).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
The included trial did not report on this outcome.
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The included trial did not report on this outcome.
Secondary Outcomes
1. Mortality
The included trial did not report on this outcome.
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2. Quality of life
The included trial did not report on this outcome.
3. Spirometric lung function
The included trial did not report on this outcome.
4. Growth and nutritional status
The included trial did not report on this outcome.
5. Frequency of respiratory exacerbations
The included trial did not report on this outcome.
6. Isolation of other micro-organisms
The included trial did not report on this outcome.
7. Adverse effects of antibiotics
Valerius did not describe cough specifically, but reported that there
were no adverse effects in either group (Valerius 1991).
Additional outcomes which have arisen during the review
1. Time to chronic infection
We defined this as the presence of P. aeruginosa in each monthly
sputum sample for six consecutive months or the presence of pre-
cipitating antibodies to P. aeruginosa or both. In the Valerius trial,
from the data provided, it was possible to calculate the propor-
tion of participants in each group who were defined as chroni-
cally colonised with P. aeruginosa from respiratory secretions at 3,
6, 12 and 24 month time points (Valerius 1991). The odds of
being chronically infected with P. aeruginosa were reduced in the
treatment group compared to the placebo group after 24 months,
OR 0.12 (95% CI 0.02 to 0.79) (Analysis 2.1). No significant
difference was detected between the two groups at the other time
points. No other trials in the review used this outcome measure
to express their findings.
2. Clinical and radiological scores
The included trial did not report on this outcome.
3. Cost
The Valerius trial did not include a health economic analysis.
Oral ciprofloxacin and inhaled colistin versus inhaled
tobramycin
This intervention comparing oral ciprofloxacin and inhaled col-
istin (three months) with inhaled tobramycin (28 days) included
only one trial including 58 participants (29 in each treatment
group) (Proesmans 2013).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
At some point in the six months following treatment, P. aeruginosa
was isolated in 10 out of 29 participants enrolled to the inhaled
colistin with oral ciprofloxacin arm compared to 16 out of 29 in
the TSI arm. The difference between groups was not statistically
significant (Analysis 3.1).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The included trial did not report on this outcome.
Secondary Outcomes
1. Mortality
There were no deaths in either arm (Proesmans 2013).
2. Quality of life
The included trial did not report on this outcome.
3. Spirometric lung function
The median change from baseline in FEV1 (% predicted) for all
the participants was -1%. The changes are not reported separately
for each treatment arm (Proesmans 2013).
4. Growth and nutritional status
Both BMI z score and weight z score were reported not to have
changed significantly for trial participants as a whole, but numer-
ical data are not reported (Proesmans 2013).
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5. Frequency of respiratory exacerbations
The authors report that, during the first six months of follow
up, there was no difference between the two treatment arms in
number of oral antibiotic treatment days. These oral antibiotics
were given for symptoms and not because of failed eradication.
However, numerical data are not reported (Proesmans 2013).
6. Isolation of other micro-organisms
The included trial did not report on this outcome.
7. Adverse effects of antibiotics
One participant is reported to have developed a severe cough with
TSI, but this result was not statistically significant (Analysis 3.2).
No other adverse effects are reported.
Additional outcomes which have arisen during the review
1. Time to chronic infection
The included trial did not report on this outcome.
2. Clinical and radiological scores
The included trial did not report on this outcome.
3. Cost
The included trial did not include a health economic analysis.
Inhaled tobramycin (28 days) versus inhaled
tobramycin (56 days)
This intervention comparing 28 days TSI with 56 days TSI in-
cluded one trial of 123 participants, of whom 88 were randomised
(Ratjen 2010).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
This outcome was not evaluated; data are presented in the paper
at one month when participants were all given the initial 28 days
of TSI before randomisation and were excluded if they had raised
anti P. aeruginosa antibody levels (Ratjen 2010).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The median time to recurrence was 26.12 months in the 28-day
treatment group and 25.82months in the 56-day treatment group.
Differences between groups were not significant (Analysis 4.1).
Secondary Outcomes
1. Mortality
There were no deaths reported (Ratjen 2010).
2. Quality of life
The included trial did not report on this outcome.
3. Spirometric lung function
The paper presented data in a table for the median change from
baseline to three months and to 27 months for FEV1% predicted,
FVC % predicted and FEF25−75 % predicted; however, presented
data were combined for both the 28-day and the 56-day treatment
groups. The paper states that there were “no major short- or long-
term changes in spirometric parameters observed during the study
period” (Ratjen 2010).
4. Growth and nutritional status
No significant differences in weight, height or body mass index
were reported. Only a summary statement was presented, indicat-
ing that the no significant difference was found in weight, height
or body mass index. No data were provided (Ratjen 2010).
5. Frequency of respiratory exacerbations
Two participants allocated to the 56-day treatment group were
hospitalised on one occasion, each for a pulmonary exacerbation.
One of these isolatedP. aeruginosa andwas treatedwith intravenous
ceftazidime and tobramycin. When entered into the analysis this
gave a non-significant result (Analysis 4.2).
6. Isolation of other micro-organisms
There were no consistent trends reported in the isolation of non-
P. aeruginosa organisms (one isolate only of Stenotrophomonas mal-
tophilia (S. maltophilia) which was seen in the 28-day arm).
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7. Adverse effects of antibiotics
Adverse events up to threemonths that were considered possibly or
probably related to treatment were reported by 14 participants in
each treatment group,with themajority being related todysphonia
in both treatment groups (11% and 14%, respectively) and cough
in the 28-day group (9%). There were no significant differences
between treatment groups for any of the reported adverse events
at any time-point (Analysis 4.3; Analysis 4.4).
Additional outcomes which have arisen during the review
1. Time to chronic infection
The included trial did not report on this outcome.
2. Clinical and radiological scores
The included trial did not report on this outcome.
3. Cost
The included trial did not have a health economic analysis.
Inhaled colistin plus oral ciprofloxacin versus inhaled
tobramycin plus oral ciprofloxacin
This comparison of inhaled colistin plus oral ciprofloxacin with
inhaled tobramycin plus oral ciprofloxacin included one trial with
223 participants (Taccetti 2012).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
In the inhaled colistin plus oral ciprofloxacin group, P. aeruginosa
was isolated within the first six months from 39 out of 105 partic-
ipants (37.1%) and in the the inhaled tobramycin plus oral cipro-
floxacin group from 41 out of 118 participants (34.7%) (Taccetti
2012). When data were analysed, the rate of isolation of P. aerugi-
nosa between the two arms was not significantly different (Analysis
5.1). At a median follow-up period of 16 months, P. aeruginosa
had been isolated from 36 out of 97 participants in the colistin
with ciprofloxacin arm for whom data were available and from 24
out of 108 participants in the tobramycin with ciprofloxacin arm;
the two arms were not significantly different. The trial authors
report that subgroup analyses by gender, age (one to five years; five
to twelve years and over twelve years), lung function (FEV1 less
than or greater than 70%) and participants with first ever isolation
of P. aeruginosa failed to show any significant differences between
groups (Taccetti 2012).
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
The trial did not report on this outcome.
Secondary Outcomes
1. Mortality
No deaths were reported (Taccetti 2012).
2. Quality of life
The trial did not report on this outcome.
3. Spirometric lung function
Following treatment, after a mean (SD) time of observation of 54
(39) days, themean (SD) relative change (percentage of predicted)
in FEV1 from baseline was 2.15 (8.50)% in the inhaled colistin
plus oral ciprofloxacin group compared to 4.55 (11.54)% in the
the inhaled tobramycin plus oral ciprofloxacin group (not statis-
tically significant) (Analysis 5.2).
4. Growth and nutritional status
The trial did not report these outcomes.
5. Frequency of respiratory exacerbations
The trial did not report this outcome.
6. Isolation of other micro-organisms
There was an observation that S. maltophilia was isolated more
frequently in the follow-up period than before eradication treat-
ment. There were no differences during follow up between the two
groups for isolation of: S. maltophilia, Achromobacter xylosoxidans
or Aspergillus species (Analysis 5.3).
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7. Adverse effects to antibiotics
There were a total of 38 out of 223 randomised participants (17%)
who discontinued treatment early; of these 17 were from the in-
haled colistin plus oral ciprofloxacin group and 21 from the in-
haled tobramycin plus oral ciprofloxacin group (Analysis 5.4).
There were a number of reasons for these discontinuations includ-
ing vomiting, photosensitivity, wheeze, pulmonary exacerbation
and lack of compliance.
Additional outcomes which have arisen during the review
1. Time to chronic infection
The trial did not report on this outcome.
2. Clinical and radiological scores
The trial did not report on this outcome.
3. Cost
A health economic analysis was not undertaken in the included
trial.
Cycled inhaled tobramycin versus culture-based
inhaled tobramycin
This comparison of cycled inhaled tobramycin (with oral cipro-
floxacin or placebo) with culture-based inhaled tobramycin (with
oral ciprofloxacin or placebo) included one trial, with 306 par-
ticipants randomised and data analysed on 304 participants who
received treatment (Treggiari 2011).
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
Treggiari reported 43 out of 148 children on cycled therapy had
one or more isolates of P. aeruginosa compared to 67 out of 150
children on culture-based therapy giving a statistically significant
effect in favour of cycled therapy, OR 0.51 (95% CI 0.31 to 0.82)
(Analysis 6.1). The main trial publication reports an age-adjusted
OR, using generalised estimating equations, with robust variance,
specifying a logit link and assuming an independence working cor-
relation (Treggiari 2011). This may explain the difference between
the trial publication and the findings of this review.
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
This was not reported in the included trial.
Secondary Outcomes
1. Mortality
No deaths were reported in either arm (Treggiari 2011).
2. Quality of life
This outcome was not reported in the included trial.
3. Spirometric lung function
The included trial reports the mean 70-week change in FEV1 %
predicted, but the mean difference between the two arms was not
significant (Analysis 6.2).
4. Growth and nutritional status
The Treggiari trial reports themean 70-week change from baseline
in weight (kg) for each treatment arm, but the MD between arms
was not significant (Analysis 6.3). The trial also reports data for the
change from baseline in height (cm) for each arm at the same time
point; again the MD between arms was not significant (Analysis
6.4).
5. Frequency of respiratory exacerbations
A primary outcome in the Treggiari trial was the time to a se-
vere pulmonary exacerbation (i.e. an exacerbation requiring in-
travenous antibiotics or hospitalisation or both) (Treggiari 2011).
The analysis shows no significant difference in time to a severe
exacerbation (Analysis 6.5).
Data on the frequency of severe exacerbations, during the 70-
week follow-up period, are also presented in the paper. From our
analysis, the data indicate no significant difference between groups
(Analysis 6.6).
Treggiari also reported a secondary outcome of time to pulmonary
exacerbation of any severity (including any exacerbation treated
with intravenous, inhaled or oral antibiotics or requiring hospital-
isation). The results of our analysis are slightly different to those
reported in the paper, but still show no statistically significant dif-
ference in time to any exacerbation (Analysis 6.7).
Finally, the number of exacerbations of any severity was also re-
ported. In our analysis, the OR was not significantly different be-
tween cycled and culture-based therapy (Analysis 6.8).
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6. Isolation of other micro-organisms
The Treggiari trial reported the number of participants in
each arm with one or more isolates of the emerging pathogen
Stenotrophomonas maltophilia (Treggiari 2011). There was no
significant difference between cycled and culture-based therapy
(Analysis 6.9).
7. Adverse effects to antibiotics
With regards to the incidence of adverse effects, Treggiari did not
report any significant difference between treatment arms, although
adverse events attributable to antibiotic therapy were not recorded
separately from adverse events which were unlikely to be related
to the study intervention (Treggiari 2011). Our results were also
not statistically significant (Analysis 6.10).
Additional outcomes which have arisen during the review
1. Time to chronic infection
This was not reported in the one included trial.
2. Clinical and radiological scores
These outcomes were not reported in the one included trial.
3. Cost
Ahealth economic analysiswas not undertaken in the one included
trial.
Ciprofloxacin versus placebo added to cycled and
culture-based inhaled tobramycin therapy
As discussed under Description of studies, the Treggari trial ran-
domised participants to cycled versus culture-based inhaled to-
bramycin therapy and then to oral ciprofloxacin versus placebo for
two weeks with each 28-day course of TSI (Treggiari 2011). This
section presents the comparison of outcomes in the ciprofloxacin
and placebo arms.
Primary outcome
1. Eradication of P. aeruginosa from the respiratory tract
a. Clearance of P. aeruginosa from BAL, sputum or
oropharyngeal cultures
Treggiari reported that 49 out of 146 children on oral ciprofloxacin
had one ormore isolates ofP. aeruginosa compared to 55 out of 150
children on placebo (Treggiari 2011). The data for this outcome
show a non-statistically significant effect. Age group-adjusted ORs
are reported in the trial paper; in our analysis, we did not adjust
for age.
b. Time to next isolation of P. aeruginosa from BAL, sputum
or oropharyngeal cultures
This was not reported in the included trial.
Secondary Outcomes
1. Mortality
No deaths were reported in either arm (Treggiari 2011).
2. Quality of life
This outcome was not reported in the included trial.
3. Spirometric lung function
The included trial reports the mean 70-week change in FEV1 %
predicted, but the MD between the two arms was not significant
(Analysis 7.2).
4. Growth and nutritional status
The Treggiari trial reports themean 70-week change from baseline
in weight (kg) for each treatment arm; the MD between arms was
not significant (Analysis 7.3). The trial also reports data for the
change from baseline in height (cm) for each arm; again the MD
between arms was not significant (Analysis 7.4).
5. Frequency of respiratory exacerbations
A primary outcome in the Treggiari trial was the time to a se-
vere pulmonary exacerbation (i.e. an exacerbation requiring intra-
venous antibiotics or hospitalisation, or both) (Treggiari 2011).
Again, for the ciprofloxacin versus placebo comparison, there was
no significant difference in time to a severe exacerbation (Analysis
7.5).
Data on the frequency of severe exacerbations, during the 70-
week follow-up period, are also presented in the paper. From our
analysis, the OR is not significantly different between groups (
Analysis 7.6).
We analysed the outcome ’time to pulmonary exacerbation (any
severity)’, including any exacerbation treated with intravenous,
inhaled or oral antibiotics or requiring hospitalisation (Analysis
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7.7). There was no difference between ciprofloxacin and placebo
in time to exacerbation (any severity).
Finally, the number of exacerbations of any severity was not sig-
nificantly different between ciprofloxacin and placebo (Analysis
7.8).
6. Isolation of other micro-organisms
In the Treggiari trial, there was no significant difference between
ciprofloxacin and placebo in the number of isolates of S. mal-
tophilia (Analysis 7.9).
7. Adverse effects to antibiotics
Treggiari did not report any significant difference between treat-
ment arms in the incidence of adverse events, although adverse
events attributable to antibiotic therapy were not recorded sep-
arately from adverse events which were unlikely to be related to
the trial intervention (Treggiari 2011). Our analysis showed no
difference between arms in the number of participants with one
or more serious adverse events (Analysis 7.10).
Additional outcomes which have arisen during the review
1. Time to chronic infection
This was not reported in the one included trial.
2. Clinical and radiological scores
These outcomes were not reported in the one included trial.
3. Cost
Ahealth economic analysiswas not undertaken in the one included
trial.
D I S C U S S I O N
Summary of main results
Our review includes seven trials (with data from 744 participants)
of antibiotic strategies for the eradication of P. aeruginosa infection
in CF, conducted over a period of over 20 years. Each trial used a
different intervention and only two trials could be combined in a
meta-analysis of the same treatment comparison. An early interim
analysis was performed due to slow accrual in one trial (Gibson
2003).
Cumulative data from 43 participants in two of the seven included
trials indicate that P. aeruginosa was more frequently eradicated
from the respiratory secretions in the participants receiving antibi-
otics than from those receiving placebo (Gibson 2003;Wiesemann
1998). This reduction in the number of isolates of P. aeruginosa
was noted at both one month and two months after the start of
treatment. A further trial suggests that the onset of chronic infec-
tion with P. aeruginosa is delayed in those individuals who have re-
ceived antibiotic therapy compared to those receiving no therapy
(Valerius 1991). There was evidence from the trials by Valerius
and Wiesemann that this effect may persist for up to 24 months
(Valerius 1991; Wiesemann 1998). We found no difference in ad-
verse events. In two trials, an increased incidence of the emerging
pathogen S. maltophilia was reported following treatment, but no
difference was found between eradication regimens in either of
these trials (Taccetti 2012; Treggiari 2011) .
The trial by Proesmans, which randomised 58 participants, was
associated with a low rate of short-term eradication of P. aeruginosa
from both groups of children treated with nebulised high-dose
tobramycin and a combination of oral ciprofloxacin with inhaled
colistin (Proesmans 2013). The numbers of participants in each
group were too low to allow comparisons of superiority between
the two eradication regimens to be made. A further possible cause
of the low eradication rate in this trial may be that participants
were recruited if they had been free of P. aeruginosa for at least
six months (with negative microbiology samples for at least six
months), which is shorter than the 12-month P. aeruginosa-free
interval used by the Leeds definition of ’Pseudomonas-free’ (Lee
2003).
The trial by Ratjen took place in 21 centres in Germany, France,
The Netherlands, UK, Spain and Austria from November 2003
until January 2008. The trial has reported that 28-day and 56-
day treatment with inhaled tobramycin to be effective and safe;
with no additional advantage to 56 days of therapy over 28 days
(Ratjen 2010). The authors of this trial concluded that head-to-
head comparisons will clarify whether adding either oral ciproflo-
xacin or intravenous antibiotic therapy can further increase treat-
ment success in people with CF with early P. aeruginosa infection.
The Taccetti trial randomised 223 participants and failed to
demonstrate superiority of inhaled tobramycin with oral cipro-
floxacin over inhaled colistin with oral ciprofloxacin, both treat-
ments given over 28 days (Taccetti 2012). As in the Ratjen trial,
the included participants had been free of P. aeruginosa for at least
six months, again at variance with the Leeds definition of Pseu-
domonas-free (Lee 2003).
The Treggiari trial was the largest trial of P. aeruginosa eradication
in CF reported so far and randomised 306 children (aged 1 to 12
years) and reported data on 304 children (Treggiari 2011). The
trial used a complex, four-arm design, comparing cycled with cul-
ture-based treatment with TSI and also additional oral ciproflo-
xacin versus placebo. The trial was adequately powered for its two
primary outcome measures (time to severe pulmonary exacerba-
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tion and proportion of P. aeruginosa positive cultures) and found
no difference between arms for either outcome. In contrast, our
analysis (which was not corrected for age) did find a significant
difference in the proportion of P. aeruginosa positive cultures in
favour of cycled therapy. There was no difference between cipro-
floxacin and placebo for this outcome.
No deaths were reported in any of the trials.
Overall completeness and applicability of
evidence
The aim of antibiotic therapy for earlyP. aeruginosa infection inCF
should be both eradication of the micro-organism and improve-
ment in (or slowing in the rate of decline of ) clinical parameters,
whilst minimising adverse effects and the isolation of new micro-
organisms. If P. aeruginosa is successfully eradicated, but there is
no measurable clinical benefit, it is likely that current measures of
clinical status are not sufficiently sensitive or that the duration of
follow up is too short to show a difference.
There are differences in the type and dose of drug administered to
the treatment groups in the two trials where nebulised tobramycin
was compared to placebo. In the Wiesemann trial, tobramycin
injectable solution was administered by nebuliser, at a low dose
(80 mg twice daily) for a long duration (12 months) (Wiesemann
1998); whereas Gibson used TSI TOBI® (now marketed by No-
vartis) at a high dose (300 mg twice daily) for a short duration (28
days) (Gibson 2003). This is a potential source of heterogeneity
between the trials. It is of interest that significant heterogeneity
was detected between the trials at the one-month time point but
this was not detected at the two-month time point.
The Proesmans andTaccetti trials included patients that werePseu-
domonas-naive and those that had not isolated P. aeruginosa for
at least six months (Proesmans 2013; Taccetti 2012), which is at
variance with the 12-month definition proposed by Lee to define
a patient as ’Pseudomonas-free’ (Lee 2003). It was not possible for
the authors of this review to extract IPD for those patients that
fit this longer definition of Pseudomonas-free. The Treggiari trial
required patients to have been free of P. aeruginosa for at least two
years (Treggiari 2011).
Eradication of isolates of P. aeruginosa is easiest in people with CF
with recent onset of P. aeruginosa infection of the respiratory tract,
in particular in those who have non-mucoid isolates of P. aerug-
inosa as they seem particularly susceptible to antibiotic therapy.
Two trials included in this review have recruited adult patients
suggesting that early P. aeruginosa infection can be eradicated from
adults as well as from children and therefore adults should be in-
cluded in future studies.
Finally, it should be noted that some of the trials were conducted
between 10 and 20 years ago and the results may be less applicable
to patients today.
Quality of the evidence
The quality of the trials was variable with important deficiencies
identified in some. For example, in four out of the seven included
trials we judged there to be a high risk from a lack of blinding
of participants and clinicians; in two of these trials the different
interventions used in the treatment and control groups precluded
blinding (Proesmans 2013; Valerius 1991) and two trials were
open label and no attempt was made at blinding. We also judged
there to be a high risk of bias due to selective reporting in three of
the trials, which only reported summary statements with no actual
data for a number of outcomes (Proesmans 2013; Ratjen 2010;
Wiesemann 1998).
While we generally judged there to be a low risk of bias due
to incomplete outcome data, there was incomplete follow up of
a number of participants in one of the older and smaller trials
(Wiesemann 1998). The absence of these data has complicated
the combined analysis of the two trials that compare inhaled to-
bramycin with placebo (Gibson 2003; Wiesemann 1998); one
trial was analysed on an intention-to-treat basis (Gibson 2003)
and another on an available-case basis (Wiesemann 1998). A sen-
sitivity analysis based on best- and worst-case scenarios demon-
strated similar results to the available-case analysis. The available-
case analysis revealed a reduction in the odds of a positive culture
for P. aeruginosa in the group treated with tobramycin inhalation
when compared to the odds in the placebo group at both one and
two months from the start of treatment (Wiesemann 1998).
The Gibson trial was stopped early because of evidence of signif-
icant treatment effect (Gibson 2003). It has been suggested that
the results of randomised controlled trials stopped early for benefit
should be interpreted with caution particularly when the number
of events is small (Montori 2005).
In the Ratjen trial, the authors wished to enrol 120 participants in
order to randomise 100 patients. They succeeded in recruiting 123
individuals ofwhom88were randomised and65 could be included
in the analysis of the primary outcome (time to recurrence of P.
aeruginosa). This trial is potentially subject to bias because of the
exclusion of non-randomised individuals, including 31 people in
whom there were elevated antibody titres to P. aeruginosa (Ratjen
2010).
The relationship between the presence of P. aeruginosa in secre-
tions from the upper respiratory tract and the isolation of P. aerug-
inosa from the lower respiratory tract is inconsistent. Reporting of
the presence of organisms in respiratory secretions is difficult to
standardise, dependent on the sampling methods used and on the
number of samples taken. The trials included in this review used
a heterogeneous mix of methods to sample respiratory secretions
from both the lower and upper respiratory tracts. No two trials
used the samemethods andmore than onemethodwas used in two
trials. There was no subgroup analysis based on sampling method
in any of the trials, probably owing to relatively small numbers of
participants in individual trials. Wiesemann used a combination
of oropharyngeal swabs and sputum samples, whereasGibson used
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oropharyngeal swabs and BAL fluid (Gibson 2003; Wiesemann
1998). Proesmans used sputum, throat swab and BAL (Proesmans
2013). The Taccetti study did not describe the technique used
for culture collection (Taccetti 2012). The Treggiari trial enrolled
younger children and used oropharyngeal swabs or sputum sam-
ples (Treggiari 2011). Armstrong has shown that the results of
oropharyngeal specimens are poorly predictive of the presence of
organisms in the lower respiratory tract (Armstrong 1996). Va-
lerius relied on sputum samples which can be of poor quality in
younger children (Valerius 1991).
Potential biases in the review process
The original review stated that trials would be included only where
eradication begins within two months of isolation of P. aerugi-
nosa. In a post hoc change, this has now been altered to include
those where eradication has been initiated up to six months since
isolation. Whilst prompt treatment of new P. aeruginosa infection
is recommended (Smyth 2014), there is no robust evidence for a
specific time limit for initiation of treatment.
The review now also includes patients from two distinct groups,
those that are Pseudomonas-naive and those that are Pseudomonas-
free.
Agreements and disagreements with other
studies or reviews
We are not aware of any other studies or reviewswhich recommend
specific eradication treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Significantly more children with cystic fibrosis (CF) show clear-
ance of Pseudomonas aeruginosa (P. aeruginosa) from their respira-
tory secretions up to three months after commencing antibiotic
therapy aimed at eradication of the organism from their respira-
tory tract when compared to placebo. This effect may last for sev-
eral months. This review has not established any improvement in
clinical outcome measures following treatment. The small num-
bers of participants in some trials and the short duration of follow
up mean that this review may have insufficient statistical power
to detect changes in these clinical outcomes. However, there are
many observational studies which have shown a decline in clinical
status once chronic P. aeruginosa infection occurs and so clinical
benefit from eradication is likely. There was no significant differ-
ence in the rate of common adverse effects detected. An increased
incidence of the emerging pathogen Stenotrophomonas maltophilia
(S. maltophilia) was seen after eradication treatment in two trials,
but there was no statistically significant difference between regi-
mens (Taccetti 2012; Treggiari 2011).
We found that nebulised antibiotics (or a combinationof nebulised
and oral antibiotics) were better than no treatment in treating early
infection with P. aeruginosa, which was eliminated in the majority
of individuals. Eradication may be sustained in the short term.We
were unable to determine whether there is an associated clinical
benefit to people with CF, though data from observational studies
suggest that benefit is likely. Overall, there is insufficient evidence
from this review to state which antibiotic strategy should be used
for the eradication of early P. aeruginosa infection in CF.
Implications for research
Whilst there is evidence that eradication treatment is more effec-
tive than placebo or no treatment, there is no evidence to help the
clinician choose which regimen to use. There remains an urgent
need for well-designed and well-executed trials, comparing erad-
ication regimens. Where possible these should evaluate whether
eradication results in appreciable clinical benefit to patients, with-
out causing them harm. Trials should also explore the influence of
prior infection with P. aeruginosa (“Pseudomonas-free” compared
to “Pseudomonas-naive”) and whether there is an advantage in early
institution of therapy (within weeks rather than within months).
This might be accomplished, using a stratified trial design. Con-
sideration should be given to appropriate outcome measures, par-
ticularly spirometric lung function, nutritional status, socio-eco-
nomic outcomes (including quality of life) and duration of follow
up. Long-term follow-up trials with careful clinical and bacterio-
logical surveillance are required. These trials will be challenging
to design and deliver. Randomisation should include two active
treatments that are both believed to be effective and safe andwould
still need to recruit a sufficient number of patients to show differ-
ences in efficacy with adequate power. Adult participants as well
as children should be included in such trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gibson 2003
Methods Double-blind RCT.
Placebo-controlled.
Parallel design.
Duration: 28 days.
Multicentre based in USA.
Participants 21 participants with a recent positive oropharyngeal culture and isolation of P. aeruginosa
from BAL at study entry.
Age: 6 months - 6 years.
Gender: 11 males, 10 females.
Interventions Treatment: Tobramycin solution for inhalation (300 mg 2x daily for 28 days)
Control: placebo inhalations.
Outcomes Eradication of P. aeruginosa, nutritional status, modified Shwachman score, adverse ef-
fects
Notes Oropharyngeal cultures performed at entry and on days 14, 28, 42 and 56 of the study.
BAL from the same lobar segment on entry and day 28
Enrolement was discontinued due to an interim analysis, precipitated by poor accrual of
participants, which showed a statistically significant microbiological effect of treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as a randomised controlled trial
stratified by study centre and age (
<
= 36
months; > 36 months), but the method of
generation of allocation sequence was not
stated
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reported as double blind, but paper did
not provide any details regarding who was
blinded or the method of blinding
We received the following helpful response
from trial authors, regarding placebo:
Active: Preservative free tobramycin sulfate,
60 mg/mL in 5 mL excipient (1/4 normal
saline, pH 6.0) in low density polyethylene
plastic ampoules inside a foil pouch (Patho-
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Gibson 2003 (Continued)
Genesis Corporation)
Placebo: 5 mL of vehicle with 1.25 mg of
quinine sulfate added as a flavouring agent,
packaged identically. PathoGenesis Corpo-
rationwere responsible for themanufacture
of the tobramycin and placebo for inhala-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on an intention-to-treat basis. Re-
ported data on all participants who were
randomised. There were no dropouts re-
ported
Selective reporting (reporting bias) Low risk No evidence of selective reporting found.
Other bias High risk Study was stopped early by the Data Mon-
itoring Committee after recruitment of 21
froman anticipated 98participants because
of statistically significant treatment effect
in favour of the tobramycin group
Study received sponsorship support from
Chiron, manufacturer of tobramycin for
inhalation as used in the study
Proesmans 2013
Methods RCT.
Parallel design.
Duration: 3 months.
Single centre based in Europe.
Participants 58 children with CF, all with new isolation of P. aeruginosa (sputum or cough swabs).
Age: median age 9 years, interquartile range (4.7 - 13.1 years)
Gender: 31 male, 27 female.
Lung function: median FEV1 at inclusion 98% predicted.
Interventions Treatment (n = 29): Inhaled TSI (300 mg 2x daily for 28 days)
Control (n = 29): 3 months combination therapy with inhaled colistin (2 MU 2x daily)
+ oral ciprofloxacin (10 mg/kg 3x daily)
Outcomes Primary outcomes
Eradication of P. aeruginosa at the end of treatment.
Secondary outcomes
Time to P. aeruginosa relapse; antibodies (Ab); IgG; FEV1; body mass index; and P.
aeruginosa status at 2-year follow up.
Notes Participants were then switched to the other arm or treatedwith IV antibiotics if clinically
indicated
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Proesmans 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in blocks of 10. No descrip-
tion given ofmethod of randomisation, nor
of any stratification
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not possible for participants and
clinicians as treatments compared were in-
haled versus inhaled and oral. No details
regarding whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis on all 58 ran-
domised participants
Selective reporting (reporting bias) High risk Protocol published on ClinicalTrials.gov
(identifier: NCT01400750). All pre-speci-
fied outcomes reported
BMI z score, weight z score and frequency
of exacerbations were reported not to have
changed significantly for trial participants,
but numerical data are not reported
Other bias Unclear risk Primary outcome was assessed at end of
treatment which was different for the 2
treatment groups 28 days for TSI partici-
pants versus 3 months for colistin/ciproflo-
xacin participants
Ratjen 2010
Methods RCT.
Parallel design.
Duration: 27 months.
Multicentre (21 centres) based in Europe (Germany, France, Spain, Austria, UK,Nether-
lands)
Participants 123 participants with CF free of P. aeruginosa (88 randomised - 31 participants not
randomised because of high P. aeruginosa antibody titres and 4 for other reasons).
Age (mean (SD)): 28-day TIS 8.7 (7.2) years, 56-day TIS 8.7 (10.5) years
Gender: 28-day TIS 26 (58%) males, 19 (42%) females; 56-day TIS 22 (51%) males,
21 (49%) females
Lung function (mean (SD) FEV1 % predicted): 28-day TIS 80.2 (18.9), 56-day TIS 87.
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Ratjen 2010 (Continued)
0 (19.2)
Interventions Group 1 (n = 45): 28 days of tobramycin solution for inhalation (TSI) (300 mg 2x daily)
, then stopped treatment
Group 2 (n = 43): 28 days of tobramycin solution for inhalation (TSI) (300 mg 2x daily)
, then randomised to a further 28 days (56 days in total)
Outcomes Primary outcome
Median time to recurrence of any strain of P. aeruginosa.
Secondary outcomes
Proportion of patients free of P. aeruginosa 1 month after the end of treatment
Number and length of hospital admissions for respiratory indications
Occurrence of other pathogens
Changes in FEV1, FVC & FEF25−75
Weight, height and body mass index.
Notes Also known as ELITE trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no descrip-
tion of randomisation techniques given
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study, no attempt at blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 65 patients from 88 randomised achieved
primary outcome.A total of 52participants
prematurely withdrawn from trial
27 participants withdrew from the 28-day
treatment group with the following rea-
sons: loss to follow up (n = 1); protocol de-
viation (n = 4); recurrence/non-eradication
(n = 21); other (n = 1)
25 participants withdrew from the 56-day
treatment group for the following reasons:
withdrawn consent (n = 1); loss to follow
up (n = 2); protocol deviation (n = 2); re-
currence/no eradication (n = 19); abnormal
audiology test (n = 1)
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Ratjen 2010 (Continued)
Selective reporting (reporting bias) High risk Study reports there were no major short-
or long-term (3 and 27 months) changes in
spirometry, but does not record the figures
for either of the 2 groups. Also, only sum-
mary statements and no numerical data are
provided for weight, height or BMI
Other bias Unclear risk Recruited fewer participants than planned;
actually randomised 88 participants (pri-
mary outcome evaluable in 65) - planned
randomisation of 100 participants
Did not randomise 35 participants from
the recruited cohort of 123 participants:
31 because of high P. aeruginosa antibody
levels, one for an adverse event, one where
consent was withdrawn, one for a protocol
deviation and one ’other’ (unspecified) rea-
son. Participants with raised antibody lev-
els were not included because the investi-
gators believed that they were chronically
infected with P. aeruginosa based on their
antibody results.
This trial was initially supported by Chi-
ron and later Novartis Pharma, the manu-
facturer of TSI
Taccetti 2012
Methods RCT.
Parallel design.
Duration: 28 days.
Multicentre (13 centres) in Italy.
Participants 223 participants with first ever or new P. aeruginosa infection. New infection defined as
P. aeruginosa isolation following bacterial clearance documented by 3 negative cultures
within the previous 6 months
Age: over 1 year.
Gender: 116 male, 107 female.
Interventions Group A (n = 105; 52 male and 53 female): 28 days 2x daily inhalation of 2 MU colistin
with 2x daily doses of ciprofloxacin 15 mg/kg/dose.
Group B (n = 118; 64 male and 54 female): 28 days therapy with TSI (300 mg 2x daily)
with 2x daily doses of ciprofloxacin 15 mg/kg/dose
Outcomes Primary outcome
P. aeruginosa eradication defined as 3 negative cultures over 6 months.
Secondary outcomes
Lung function (FEV1).
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Taccetti 2012 (Continued)
Period of time free of P. aeruginosa.
Isolation of other pathogens including gram-negative and aspergillus
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence generated by sta-
tistical software within permuted blocks
of size 10, stratified according to age and
FEV1.
Allocation concealment (selection bias) Low risk Separation of individuals responsible for
randomisation and treatment assignment
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label trial so no blinding of partici-
pants nor researchers
Incomplete outcome data (attrition bias)
All outcomes
Low risk 38 of 223 randomised participants (17%)
dropped out of the trial. The biggest reason
for dropping out was lack of compliance
with follow up protocol (11 from Group A
and 13 from Group B) and identification
of a pulmonary exacerbation during early
eradication therapy (4 fromGroup A and 5
from Group B). Analysis was by intention-
to-treat
Selective reporting (reporting bias) Unclear risk We have been unable to locate a published
protocol for this trial. The details pub-
lished on the EudraCT database (number
2008-006502-42) describe objectives but
not outcomes. In themain paper, themeth-
ods section does not describe all the trial
objectives. Only eradication, time free of
P. aeruginosa and spirometry are described
in the methods section. These outcomes
plus the additional outcomes of isolation
of other organisms and adverse events are
described in the results
Other bias Low risk No evidence of other bias identified.
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Treggiari 2011
Methods RCT.
Multi-centre (57 centres) in the USA.
Trial duration for each participant is 18 months.
Parallel design.
Inhaled tobramycin was provided in an open-label fashion, while oral ciprofloxacin was
provided in a double-blinded fashion
Participants 306 participants with CF, previously free of P. aeruginosa or had not had positive isolates
for 2 years or more.
Age: 1 year or older and 12 years and younger.
Gender: 150 male, 154 female.
Interventions All participants received eradication therapy with inhaled tobramycin (Novartis Phar-
maceutical Corp) for 28 days with or without ciprofloxacin (Bayer Healthcare AG). The
main randomised intervention of nebulised tobramycin, with or without oral ciproflo-
xacin, commenced after this initial 28 days of treatment:
Group A: cycled therapy;
Group B: culture-based therapy.
Furthermore, the time from isolation of P. aeruginosa to commencing trial therapy was
up to 6 months and in this interval, some participants received antimicrobial therapy
Outcomes Primary outcomes
Time to first exacerbation requiring IV therapy.
Proportion of positive cultures in each group.
Secondary outcomes
Clinical
Time to pulmonary exacerbation not requiring IV antibiotic usage or hospitalization
Frequency of pulmonary exacerbations, hospitalizations, and use of concomitant oral,
inhaled, and IV antibiotics
Anthropometric measures (linear growth, weight gain).
Pulmonary function tests including FVC, FEF25%−75%, and FEV1 (participants 4 years
of age and older, able to reproducibly perform spirometry)
Total hospitalization days.
Microbiological
Changes in antibiotic susceptibility patterns (minimal inhibitory concentrations of 12
antibiotics)
Colony morphology.
Presence of mucoid isolates from baseline to the end of the trial
Emergence of intrinsically aminoglycoside and ciprofloxacin-resistant non-pseudomonal
organisms (e.g. B. cepacia, A. xylosoxidans, and S. maltophilia).
Adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Treggiari 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Randomization was carried out by per-
muted blocks, and performed using a com-
puter-generated sequence
Allocation concealment (selection bias) Low risk Randomization assignmentwas available at
the sites via an interactive voice response
system with e-mail confirmation of the
treatment assignment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Inhaled tobramycin was provided in an
open-label fashion, while oral ciprofloxacin
was provided in a double-blinded fashion
All trial personnel and participants were
blinded to oral therapy assignment but not
to cycled or culture-based treatment allo-
cation. The core trial investigators were
blinded to all treatment allocation for the
entire study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 of 306 randomised participants ex-
cluded from the analysis (because they did
not receive study treatment)
Selective reporting (reporting bias) Low risk Data on all primary and secondary out-
comes reported.
Other bias Low risk No imbalance in baseline characteristics.
Central trial team (not local investigators)
blinded
Valerius 1991
Methods RCT.
Parallel design.
Duration: 27 months.
Single-centre trial based in Europe.
Participants 26 participants with a recent positive culture who have never received anti-pseudomonal
therapy
Age: 2 - 9 years.
Gender: 13 males, 13 females.
Interventions Treatment: oral ciprofloxacin (250 - 750 mg) 2x daily and inhaled colistin (1 MU) for
3 weeks at entry and each time P. aeruginosa isolated.
Control: no anti-pseudomonas chemotherapy.
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Valerius 1991 (Continued)
Outcomes Time to chronic colonisation with P. aeruginosa (defined as the presence of P. aeruginosa
in monthly routine sputum specimens for 6 consecutive months and/or the development
of precipitating serum antibodies against P. aeruginosa).
Notes Monthly sputum samples.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as a RCT without stratification,
but the method of generation of allocation
sequence was not stated
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Did not use blinding, interventions differ-
ent.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed on an intention-to-treat basis. Re-
ported data on all participants who were
randomised. There were no dropouts re-
ported
Selective reporting (reporting bias) Low risk No evidence of selective reporting found.
Other bias Low risk No evidence of other bias identified.
Wiesemann 1998
Methods RCT.
Double-blind, placebo-controlled trial.
Parallel design.
Duration: 2 years.
Multicentre trial based in Europe.
Participants 22 children with P. aeruginosa-negative throat swabs or sputum cultures for > 1 year and
negative serum antibody titers were eligible
Age: 4 - 18 years.
Gender: 9 males, 13 females.
Interventions Treatment: nebulised tobramycin 80 mg inhaled 2x daily.
Control: inhaled placebo.
Outcomes Time to clearance of P. aeruginosa from the airway.
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Wiesemann 1998 (Continued)
Notes Monthly sputum or oropharyngeal swabs during trial period.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence was generated using a
coin flip for pairs of participants. There is
no information as to who was responsible
for the coin flip or what controls were in
place to ensure validity of the result of the
coin flip
Allocation concealment (selection bias) Unclear risk Did not report how allocation was con-
cealed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Reported as double blind. Participantswere
blinded by providing a placebo inhalation
with a similar taste to the treatment in-
halation, but it is not clear whether the
clinicians administering the treatmentwere
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 out of 11 participants withdrew from
treatment group; 5 out of 11 participants
withdrew from placebo group. The trial
was analysed on an available case basis
Selective reporting (reporting bias) High risk Reported there was no change in spiromet-
ric pulmonary function during or after the
treatment period, but no data were given
Other bias Low risk No evidence of other bias identified.
BAL: bronchoalveolar lavage
FEF25−75: mid-forced expiratory flow
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
IgG: immunoglobulin G
IV: intravenous
MU: million units
P. aeruginosa: Pseudomonas aeruginosa
RCT: randomised controlled trial
TSI: tobramycin solution for inhalation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alothman 2002 Drug tolerability study, not eradication therapy.
Alothman 2005 Drug tolerability study, not eradication therapy.
Ballman 1998 Eradication treatment not used. Observational study.
Brett 1992 Participants allocated to treatment by minimisation on the basis of IgG levels and clinical indications
compared to therapy based on clinical indications alone
Church 1997 Symptomatic treatment not eradication.
Clancy 2013 Participants chronically infected with P. aeruginosa.
Coates 2011 Participants chronically infected with P. aeruginosa.
Frederiksen 1997 Historical control group.
Geller 2007 Pharmacokinetic and drug tolerability study, not eradication therapy
Gibson 2007 Not randomised and with no allocation concealment.
Goss 2009 Participants chronically infected with P. aeruginosa.
Griese 2002 Case-control study.
Heinzl 2002 No control group.
Kenny 2009 Retrospective cohort study.
Konstan 2010 Participants chronically infected with P. aeruginosa.
Latzin 2008 The primary aim of this trial was not to evaluate eradication regimens for P. aeruginosa and 112 of 118
participants were treated for an acute exacerbation or suppression of chronic infection with P. aeruginosa.
Lenoir 2007 Trial not designed to look at eradication of P. aeruginosa. At baseline, 47 of 59 participants had chronic
infection with P. aeruginosa.
Littlewood 1985 No control group.
Mainz 2014 Sinonasal nebulisation of antibiotic aiming to eradicate from the sinuses only
Mazurek 2012 Participants chronically infected with P. aeruginosa.
Oermann 2009 Participants chronically infected with P. aeruginosa, not an eradication trial, no randomisation.
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(Continued)
Postnikov 2000 No control group and no randomisation.
Postnikov 2007 Not an eradication trial, participants chronically infected with P. aeruginosa.
Prayle 2013 Participants chronically infected with P. aeruginosa.
Ramsey 1999 Participants chronically infected with P. aeruginosa.
Ratjen 2001a No control group.
Retsch-Bogart 2008 Participants chronically infected with P. aeruginosa.
Retsch-Bogart 2009 Participants chronically infected with P. aeruginosa.
Rietschel 2009 Pharmacokinetic study of inhaled tobramycin, not eradication therapy
Schaad 1997 Symptomatic treatment not eradication.
Schelstraete 2010 No randomisation or eradication therapy.
Schuster 2013 Drug tolerability study in chronic P. aeruginosa infection, not eradication therapy.
Steinkamp 1989 No control group.
Steinkamp 2007 Participants chronically infected with P. aeruginosa.
Taccetti 2005 Primary outcome did not have a control group. Historical controls utilised for other outcomes. No
randomisation
Tramper-Stranders 2009 Study of prophylaxis against future infection with P. aeruginosa, not of eradication.
Trapnell 2012 Participants chronically infected with P. aeruginosa.
Vazquez 1993 Historical control group.
Wainwright 2011a Randomised to therapy directed by the results of bronchoalveolar lavage compared to therapy based on
clinical indications or upper respiratory samples
Wainwright 2011b Participants chronically infected with P. aeruginosa.
P. aeruginosa: Pseudomonas aeruginosa
46Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Noah 2010
Methods Single-centre, randomised, prospective trial.
Participants Stable children with CF and positive surveillance cultures for P. aeruginosa.
Interventions Nebulised tobramycin 300 mg 2x daily for 4 weeks or intravenous ceftazidime with tobramycin for 2 weeks at
standard weight-adjusted doses
Outcomes Primary efficacy endpointwas change inBALfluid percentage neutrophils from themost affected lobe at bronchoscopy
Secondary outcomes included change in BAL fluid differential cell counts, cytokines and bacterial quantity
Notes 8 participants from a total of 15 had first ever isolate of P. aeruginosa and can be included in this review. Outcome
data for these 8 participants not published, author contacted for them
BAL: bronchoalveolar lavage
CF: cystic fibrosis
P. aeruginosa: Pseudomonas aeruginosa
Characteristics of ongoing studies [ordered by study ID]
TORPEDO Trial
Trial name or title TORPEDO-CF (Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis)
Methods Multi-centre, parallel group, RCT.
Participants Inclusion criteria
1. Diagnosis of CF
2. Children over the age of 28 days, older children and adult CF participants are all eligible with no upper
age limitation
3. Competent adults should provide fully informed written consent to participate in the trial
4.Minors should have proxy consent by the parent or legal guardian and should provide assentwhere applicable
to participate in the trial
5. The participant should have isolated P.aeruginosa and should be either:
a. P. aeruginosa-naïve (i.e. has never previously isolated P. aeruginosa) or
b. P. aeruginosa-free (i.e. a minimum of four consecutive cough or sputum samples should be P. aeruginosa-
free within a 12-month period)
6. The participant should be able to commence treatment no later than 21 days from the date of a P. aeruginosa
positive microbiology report
Interventions Objective: this trial will assess whether 10 days IV ceftazidime with tobramycin is superior to 3 months oral
ciprofloxacin. Both treatment regimes will be in conjunction with 3 months nebulised colistin
Arm A: 14 days IV ceftazidime 50 mg/kg/dose, to a maximum of 3 g 3x daily and IV tobramycin 10 mg/kg/
day either 1x daily or in divided doses (maximum 660 mg/day).
Arm B: 3 months oral ciprofloxacin 2x daily (ciprofloxacin dose will be 15 - 20 mg/kg/dose 2x daily for
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TORPEDO Trial (Continued)
children aged < 5 years and 20 mg/kg/dose 2x daily (maximum 750 mg 2x daily) for those aged ≥ 5 years).
Both treatment arms will receive 3 months of nebulised colistin in conjunction to the randomised treatment.
Colistin dose will be as recommended by the UK CF Trust: 1,000,000 units 2x daily for children aged ≤ 2
years and 2,000,000 units 2x daily for children aged > 2 years and adults
Outcomes Primary outcome
1. Successful eradication of P. aeruginosa infection 3 months after allocated treatment has started, remaining
infection-free through to 15 months after the start of allocated treatment
Secondary outcomes
1. Time to reoccurrence of original P. aeruginosa infection
2. Re-infection with a different genotype of P. aeruginosa
3. Lung function (FEV1 , FVC, FEF25−75)
4. O2 saturation
5. Growth and nutritional status - height, weight and body mass index
6. Number of pulmonary exacerbations
7. Admission to hospital
8. Number of days spent as inpatient in hospital over the 3-month period after allocated treatment has
finished, and between 3 months and 15 months after eradication treatment has finished (other than 14 days
spent on initial IV treatment)
9. Quality of life (CFQ)
10. Utility (EQ-5D)
11. Adverse events
12. Other sputum/cough microbiology (MRSA, B. cepacia complex, Aspergillus, candida infection)
13. Cost per patient (from NHS perspective)
14. Incremental cost effectiveness ratio (cost per successfully treated patient, cost per QALY)
15. Carer burden (absenteeism from school or work)
16. Participant burden (absenteeism from education or work)
Starting date 24/05/2010.
Contact information Dr Simon Langton Hewer
Bristol Royal Hospital for Children
Paul O’Gorman Building
Upper Maudlin Street
Bristol
BS2 8BJ
UK
Notes Anticipated end date: 01/11/2014
HTA 07/51/01
A. xylosoxidans: Alcaligenes xylosoxidans
B. cepacia: Burkholderia cepacia
CF: cystic fibrosis
FEF25−75: mid-forced expiratory flow
FEV1: forced expiratory volume at 1 second
FVC: forced vital capacity
IV: intravenous
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MRSA: Methicillin-resistant Staphylococcus aureus
NHS: National Health Service
O2: oxygen
od: once daily
P. aeruginosa: Pseudomonas aeruginosa
QALY: quality-adjusted life year
RCT: randomised controlled trial
S. maltophilia: Stenotrophomonous maltophilia
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D A T A A N D A N A L Y S E S
Comparison 1. Inhaled tobramycin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive respiratory culture for P.
aeruginosa (300 mg 2x daily)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 1 month 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 2 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Positive respiratory culture for P.
aeruginosa (80 mg 2x daily)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 At 1 month 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 2 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 At 3 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 At 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 At 12 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Positive respiratory culture for P.
aeruginosa (combined available
case analysis)
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 At 1 month 2 38 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.33]
3.2 At 2 months 2 38 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.03, 0.65]
4 Positive respiratory culture for
P. aeruginosa (combined) - best
case
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 At 1 month 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.30]
4.2 At 2 months 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.03, 0.60]
4.3 At 3 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.16]
4.4 At 6 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.48]
4.5 At 12 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.01 [3.32, 0.26]
5 Positive respiratory culture for P.
aeruginosa (combined) - worst
case
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At 1 month 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.02, 0.38]
5.2 At 2 months 2 39 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.73]
5.3 At 3 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.05, 2.77]
5.4 At 6 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 1.83]
5.5 At 12 months 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.05, 2.77]
6 Change in weight from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in modified
Shwachmann score from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 At 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Oral ciprofloxacin and inhaled colistin versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion colonised with P.
aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 3 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 12 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive respiratory culture for
P.aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 In first 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Severe cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Nebulised tobramycin 28 days versus 56 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to next isolation of P.
aeruginosa from BAL, sputum
or oropharyngeal cultures
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
2 Number of respiratory
exacerbations
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Until recurrence of P.
aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events (up to 3 months) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Productive cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Haemoptysis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Rhinitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Sinusitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Nasopharyngitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Tonsilitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Oropharyngeal pain 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Dysphonia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3.10 Headache 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 URTI 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.12 Lung disorder 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.13 Bronchitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.14 P. aeruginosa infection 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Influenza 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Otitis media 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Deafness 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.18 Drug level increased 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.19 Pyrexia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.20 Vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.21 Varicella 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (over 3 months) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Productive cough 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Haemoptysis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Rhinitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Sinusitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Nasopharyngitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Tonsilitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Oropharyngeal pain 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Dysphonia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Headache 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 URTI 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Lung disorder 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.13 Bronchitis 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.14 P. aeruginosa infection 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.15 Influenza 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.16 Otitis media 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.17 Deafness 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.18 Drug level increased 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.19 Pyrexia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.20 Vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.21 Varicella 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive respiratory culture for P.
aeruginosa
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 In first 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At end of follow up
(median 16 months)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Relative change in % predicted
FEV1 from baseline (to mean
54 days)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Post-trial microbiology status 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
52Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.1 Stenotrophomonas
maltophilia
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Achromobacter xylosoxidans 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Aspergillus species 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events leading to trial
discontinuation
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Photosensitivity 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Wheeze 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Pulmonary exacerbation
during early eradication
treatment
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Lack of compliance 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with one or more
isolates of P. aeruginosa from
respiratory tract
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
2 Mean 70-week change in FEV1
% predicted
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Mean 70-week change in weight
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Mean 70-week change in height
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Time to severe pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
6 Participants with one or more
severe pulmonary exacerbations
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
7 Time to pulmonary exacerbation
(any severity)
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
8 Participants with one or more
pulmonary exacerbations (any
severity)
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
9 Participants with new isolates of
Stenotrophomonas maltophilia
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
10 Participants with one or more
serious adverse event
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
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Comparison 7. Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with one or more
isolates of P. aeruginosa from
respiratory tract
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
2 Mean 70-week change in FEV1
% predicted
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Mean 70-week change in weight
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Mean 70-week change in height
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Time to severe pulmonary
exacerbation
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
6 Participants with one or more
severe pulmonary exacerbations
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
7 Time to pulmonary exacerbation
(any severity)
1 Hazard Ratio (Fixed, 95% CI) Totals not selected
8 Participants with one of more
pulmonary exacerbation (any
severity)
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
9 Participants with new isolates of
Stenotrophomonas maltophilia
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
10 Participants with one or more
serious adverse event
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Inhaled tobramycin versus placebo, Outcome 1 Positive respiratory culture for
P. aeruginosa (300 mg 2x daily).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 1 Positive respiratory culture for P. aeruginosa (300 mg 2x daily)
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 0.01 [ 0.00, 0.30 ]
2 At 2 months
Gibson 2003 2/8 8/13 0.21 [ 0.03, 1.47 ]
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.2. Comparison 1 Inhaled tobramycin versus placebo, Outcome 2 Positive respiratory culture for
P. aeruginosa (80 mg 2x daily).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 2 Positive respiratory culture for P. aeruginosa (80 mg 2x daily)
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Wiesemann 1998 3/8 7/9 0.17 [ 0.02, 1.44 ]
2 At 2 months
Wiesemann 1998 2/8 7/9 0.10 [ 0.01, 0.90 ]
3 At 3 months
Wiesemann 1998 2/8 4/7 0.25 [ 0.03, 2.24 ]
4 At 6 months
Wiesemann 1998 1/9 4/6 0.06 [ 0.00, 0.92 ]
5 At 12 months
Wiesemann 1998 1/8 4/4 0.02 [ 0.00, 0.67 ]
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.3. Comparison 1 Inhaled tobramycin versus placebo, Outcome 3 Positive respiratory culture for
P. aeruginosa (combined available case analysis).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 3 Positive respiratory culture for P. aeruginosa (combined available case analysis)
Study or subgroup Tobramycin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 67.4 % 0.01 [ 0.00, 0.30 ]
Wiesemann 1998 3/8 7/9 32.6 % 0.17 [ 0.02, 1.44 ]
Subtotal (95% CI) 16 22 100.0 % 0.06 [ 0.01, 0.33 ]
Total events: 3 (Tobramycin), 18 (Placebo)
Heterogeneity: Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 3.32 (P = 0.00091)
2 At 2 months
Gibson 2003 2/8 7/9 51.9 % 0.10 [ 0.01, 0.90 ]
Wiesemann 1998 2/8 8/13 48.1 % 0.21 [ 0.03, 1.47 ]
Subtotal (95% CI) 16 22 100.0 % 0.15 [ 0.03, 0.65 ]
Total events: 4 (Tobramycin), 15 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.4. Comparison 1 Inhaled tobramycin versus placebo, Outcome 4 Positive respiratory culture for
P. aeruginosa (combined) - best case.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 4 Positive respiratory culture for P. aeruginosa (combined) - best case
Study or subgroup Tobramycin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 64.6 % 0.01 [ 0.00, 0.30 ]
Wiesemann 1998 3/9 7/9 35.4 % 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 17 22 100.0 % 0.06 [ 0.01, 0.30 ]
Total events: 3 (Tobramycin), 18 (Placebo)
Heterogeneity: Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 3.42 (P = 0.00063)
2 At 2 months
Gibson 2003 2/8 8/13 45.6 % 0.21 [ 0.03, 1.47 ]
Wiesemann 1998 2/9 7/9 54.4 % 0.08 [ 0.01, 0.75 ]
Subtotal (95% CI) 17 22 100.0 % 0.14 [ 0.03, 0.60 ]
Total events: 4 (Tobramycin), 15 (Placebo)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0080)
3 At 3 months
Wiesemann 1998 2/9 6/9 100.0 % 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 9 9 100.0 % 0.14 [ 0.02, 1.16 ]
Total events: 2 (Tobramycin), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
4 At 6 months
Wiesemann 1998 1/9 7/9 100.0 % 0.04 [ 0.00, 0.48 ]
Subtotal (95% CI) 9 9 100.0 % 0.04 [ 0.00, 0.48 ]
Total events: 1 (Tobramycin), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
5 At 12 months
Wiesemann 1998 1/9 9/9 100.0 % 0.01 [ 0.00, 0.26 ]
Subtotal (95% CI) 9 9 100.0 % 0.01 [ 0.00, 0.26 ]
Total events: 1 (Tobramycin), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0059)
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.5. Comparison 1 Inhaled tobramycin versus placebo, Outcome 5 Positive respiratory culture for
P. aeruginosa (combined) - worst case.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 5 Positive respiratory culture for P. aeruginosa (combined) - worst case
Study or subgroup Tobramycin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Gibson 2003 0/8 11/13 68.6 % 0.01 [ 0.00, 0.30 ]
Wiesemann 1998 4/9 7/9 31.4 % 0.23 [ 0.03, 1.77 ]
Subtotal (95% CI) 17 22 100.0 % 0.08 [ 0.02, 0.38 ]
Total events: 4 (Tobramycin), 18 (Placebo)
Heterogeneity: Chi2 = 2.30, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 At 2 months
Gibson 2003 2/8 8/13 49.5 % 0.21 [ 0.03, 1.47 ]
Wiesemann 1998 3/9 7/9 50.5 % 0.14 [ 0.02, 1.16 ]
Subtotal (95% CI) 17 22 100.0 % 0.18 [ 0.04, 0.73 ]
Total events: 5 (Tobramycin), 15 (Placebo)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
3 At 3 months
Wiesemann 1998 2/9 4/9 100.0 % 0.36 [ 0.05, 2.77 ]
Subtotal (95% CI) 9 9 100.0 % 0.36 [ 0.05, 2.77 ]
Total events: 2 (Tobramycin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.32)
4 At 6 months
Wiesemann 1998 1/9 4/9 100.0 % 0.16 [ 0.01, 1.83 ]
Subtotal (95% CI) 9 9 100.0 % 0.16 [ 0.01, 1.83 ]
Total events: 1 (Tobramycin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
5 At 12 months
Wiesemann 1998 2/9 4/9 100.0 % 0.36 [ 0.05, 2.77 ]
Subtotal (95% CI) 9 9 100.0 % 0.36 [ 0.05, 2.77 ]
Total events: 2 (Tobramycin), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.32)
0.001 0.01 0.1 1 10 100 1000
Favours tobramycin Favours placebo
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Analysis 1.6. Comparison 1 Inhaled tobramycin versus placebo, Outcome 6 Change in weight from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 6 Change in weight from baseline
Study or subgroup Tobramycin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Gibson 2003 8 0.3 (0.5) 13 0.1 (0.6) 0.20 [ -0.28, 0.68 ]
2 At 2 months
Gibson 2003 8 0.4 (0.5) 13 0.3 (0.6) 0.10 [ -0.38, 0.58 ]
-4 -2 0 2 4
Favours tobramycin Favours placebo
Analysis 1.7. Comparison 1 Inhaled tobramycin versus placebo, Outcome 7 Adverse events.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 7 Adverse events
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Gibson 2003 7/8 12/13 0.58 [ 0.03, 10.86 ]
0.01 0.1 1 10 100
Favours tobramycin Favours placebo
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Analysis 1.8. Comparison 1 Inhaled tobramycin versus placebo, Outcome 8 Change in modified
Shwachmann score from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 1 Inhaled tobramycin versus placebo
Outcome: 8 Change in modified Shwachmann score from baseline
Study or subgroup Tobramycin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Gibson 2003 8 0.5 (2.4) 13 -0.8 (6) 1.30 [ -2.36, 4.96 ]
2 At 2 months
Gibson 2003 8 2.4 (3.4) 13 -1.4 (6) 3.80 [ -0.22, 7.82 ]
-10 -5 0 5 10
Favours placebo Favours tobramycin
Analysis 2.1. Comparison 2 Oral ciprofloxacin and inhaled colistin versus no treatment, Outcome 1
Proportion colonised with P. aeruginosa.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 2 Oral ciprofloxacin and inhaled colistin versus no treatment
Outcome: 1 Proportion colonised with P. aeruginosa
Study or subgroup Anti-pseudo Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Valerius 1991 1/14 0/12 2.78 [ 0.10, 74.70 ]
2 At 6 months
Valerius 1991 1/14 1/12 0.85 [ 0.05, 15.16 ]
3 At 12 months
Valerius 1991 2/14 6/12 0.17 [ 0.03, 1.09 ]
4 At 24 months
Valerius 1991 2/14 7/12 0.12 [ 0.02, 0.79 ]
0.001 0.01 0.1 1 10 100 1000
Favours anti-pseudo Favours control
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Analysis 3.1. Comparison 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin, Outcome 1
Positive respiratory culture for P.aeruginosa.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin
Outcome: 1 Positive respiratory culture for P.aeruginosa
Study or subgroup
Ciprofloxacin
% Inhaled
colistin Inhaled tobramycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In first 6 months
Proesmans 2013 10/29 16/29 0.43 [ 0.15, 1.23 ]
2 At 24 months
Proesmans 2013 (1) 9/23 11/24 0.76 [ 0.24, 2.42 ]
0.01 0.1 1 10 100
Favours cipro % colistin Favours tobramycin
(1) Only 23/29 colistin/ciproflxacin % 24/29 TSI treated patients followed up to 24 months
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Analysis 3.2. Comparison 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin, Outcome 2
Adverse events.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 3 Oral ciprofloxacin and inhaled colistin versus inhaled tobramycin
Outcome: 2 Adverse events
Study or subgroup
Ciprofloxacin
% Inhaled
colistin Inhaled tobramycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Severe cough
Proesmans 2013 0/29 1/29 0.32 [ 0.01, 8.24 ]
0.01 0.1 1 10 100
Favours Ciprofloxacin % Inhaled colistin Favours Inhaled tobramycin
Analysis 4.1. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 1 Time to next
isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 1 Time to next isolation of P. aeruginosa from BAL, sputum or oropharyngeal cultures
Study or subgroup Favours TIS 56 days TIS 28 days log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ratjen 2010 31 34 -0.21 (0.3963) 0.81 [ 0.37, 1.76 ]
0.05 0.2 1 5 20
Favours TIS 56 days Favours TIS 28 days
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Analysis 4.2. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 2 Number of
respiratory exacerbations.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 2 Number of respiratory exacerbations
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Until recurrence of P. aeruginosa
Ratjen 2010 0/44 2/43 0.19 [ 0.01, 4.00 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
Analysis 4.3. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 3 Adverse events (up to
3 months).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 3 Adverse events (up to 3 months)
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Ratjen 2010 9/44 2/43 5.27 [ 1.07, 26.04 ]
2 Productive cough
Ratjen 2010 1/44 2/43 0.48 [ 0.04, 5.46 ]
3 Haemoptysis
Ratjen 2010 2/44 1/43 2.00 [ 0.17, 22.91 ]
4 Rhinitis
Ratjen 2010 7/44 3/43 2.52 [ 0.61, 10.48 ]
5 Sinusitis
Ratjen 2010 0/44 0/43 Not estimable
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
(Continued . . . )
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(. . . Continued)
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Nasopharyngitis
Ratjen 2010 3/44 0/43 7.34 [ 0.37, 146.43 ]
7 Tonsilitis
Ratjen 2010 1/44 0/43 3.00 [ 0.12, 75.69 ]
8 Oropharyngeal pain
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
9 Dysphonia
Ratjen 2010 5/44 6/43 0.79 [ 0.22, 2.81 ]
10 Headache
Ratjen 2010 3/44 1/43 3.07 [ 0.31, 30.77 ]
11 URTI
Ratjen 2010 4/44 2/43 2.05 [ 0.36, 11.83 ]
12 Lung disorder
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
13 Bronchitis
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
14 P. aeruginosa infection
Ratjen 2010 2/44 1/43 2.00 [ 0.17, 22.91 ]
15 Influenza
Ratjen 2010 2/44 0/43 5.12 [ 0.24, 109.77 ]
16 Otitis media
Ratjen 2010 0/44 1/43 0.32 [ 0.01, 8.03 ]
17 Deafness
Ratjen 2010 0/44 2/43 0.19 [ 0.01, 4.00 ]
18 Drug level increased
Ratjen 2010 2/44 1/43 2.00 [ 0.17, 22.91 ]
19 Pyrexia
Ratjen 2010 3/44 4/43 0.71 [ 0.15, 3.39 ]
20 Vomiting
Ratjen 2010 1/44 1/43 0.98 [ 0.06, 16.13 ]
21 Varicella
Ratjen 2010 0/44 1/43 0.32 [ 0.01, 8.03 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
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Analysis 4.4. Comparison 4 Nebulised tobramycin 28 days versus 56 days, Outcome 4 Adverse events (over
3 months).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 4 Nebulised tobramycin 28 days versus 56 days
Outcome: 4 Adverse events (over 3 months)
Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Ratjen 2010 9/35 7/36 1.43 [ 0.47, 4.40 ]
2 Productive cough
Ratjen 2010 0/35 1/36 0.33 [ 0.01, 8.46 ]
3 Haemoptysis
Ratjen 2010 1/35 0/36 3.17 [ 0.13, 80.58 ]
4 Rhinitis
Ratjen 2010 3/35 2/36 1.59 [ 0.25, 10.17 ]
5 Sinusitis
Ratjen 2010 2/35 0/36 5.45 [ 0.25, 117.63 ]
6 Nasopharyngitis
Ratjen 2010 0/35 2/36 0.19 [ 0.01, 4.20 ]
7 Tonsilitis
Ratjen 2010 4/35 1/36 4.52 [ 0.48, 42.59 ]
8 Oropharyngeal pain
Ratjen 2010 2/35 0/36 5.45 [ 0.25, 117.63 ]
9 Dysphonia
Ratjen 2010 0/35 0/36 Not estimable
10 Headache
Ratjen 2010 0/35 0/36 Not estimable
11 URTI
Ratjen 2010 4/35 4/36 1.03 [ 0.24, 4.50 ]
12 Lung disorder
Ratjen 2010 1/35 2/36 0.50 [ 0.04, 5.78 ]
13 Bronchitis
Ratjen 2010 3/35 4/36 0.75 [ 0.16, 3.62 ]
14 P. aeruginosa infection
Ratjen 2010 1/35 1/36 1.03 [ 0.06, 17.13 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
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Study or subgroup 28-day TIS 56-day TIS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Influenza
Ratjen 2010 0/35 0/36 Not estimable
16 Otitis media
Ratjen 2010 3/35 2/36 1.59 [ 0.25, 10.17 ]
17 Deafness
Ratjen 2010 0/35 0/36 Not estimable
18 Drug level increased
Ratjen 2010 0/35 0/36 Not estimable
19 Pyrexia
Ratjen 2010 2/35 2/36 1.03 [ 0.14, 7.75 ]
20 Vomiting
Ratjen 2010 0/35 3/36 0.13 [ 0.01, 2.71 ]
21 Varicella
Ratjen 2010 0/35 3/36 0.13 [ 0.01, 2.71 ]
0.005 0.1 1 10 200
Favours 28-day TIS Favours 56-day TIS
66Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.1. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 1 Positive respiratory culture for P. aeruginosa.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 1 Positive respiratory culture for P. aeruginosa
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In first 6 months
Taccetti 2012 39/105 41/118 1.11 [ 0.64, 1.92 ]
2 At end of follow up (median 16 months)
Taccetti 2012 36/97 34/108 1.28 [ 0.72, 2.29 ]
0.5 0.7 1 1.5 2
Favours colistin/cipro Favours tobramycin/cipro
Analysis 5.2. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 2 Relative change in % predicted FEV1 from baseline (to mean 54 days).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 2 Relative change in % predicted FEV1 from baseline (to mean 54 days)
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Taccetti 2012 60 2.15 (8.5) 68 4.55 (11.54) -2.40 [ -5.89, 1.09 ]
-10 -5 0 5 10
Favours tobramycin/cipro Favours colistin/cipro
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Analysis 5.3. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 3 Post-trial microbiology status.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 3 Post-trial microbiology status
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Stenotrophomonas maltophilia
Taccetti 2012 18/97 22/108 0.89 [ 0.45, 1.78 ]
2 Achromobacter xylosoxidans
Taccetti 2012 8/97 6/108 1.53 [ 0.51, 4.57 ]
3 Aspergillus species
Taccetti 2012 10/97 21/108 0.48 [ 0.21, 1.07 ]
0.05 0.2 1 5 20
Favours colistin/cipro Favours tobramycin/cipro
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Analysis 5.4. Comparison 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin,
Outcome 4 Adverse events leading to trial discontinuation.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 5 Inhaled colistin/oral ciprofloxacin versus inhaled tobramycin/oral ciprofloxacin
Outcome: 4 Adverse events leading to trial discontinuation
Study or subgroup Colistin/ciprofloxacin Tobramycin/ciprofloxacin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vomiting
Taccetti 2012 1/105 2/118 0.56 [ 0.05, 6.24 ]
2 Photosensitivity
Taccetti 2012 1/105 0/118 3.40 [ 0.14, 84.41 ]
3 Wheeze
Taccetti 2012 0/105 1/118 0.37 [ 0.01, 9.21 ]
4 Pulmonary exacerbation during early eradication treatment
Taccetti 2012 4/105 5/118 0.90 [ 0.23, 3.42 ]
5 Lack of compliance
Taccetti 2012 11/105 13/118 0.95 [ 0.40, 2.21 ]
0.01 0.1 1 10 100
Favours colistin/cipro Favours tobramycin/cipro
Analysis 6.1. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
1 Participants with one or more isolates of P. aeruginosa from respiratory tract.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 1 Participants with one or more isolates of P. aeruginosa from respiratory tract
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 43/148 67/150 0.51 [ 0.31, 0.82 ]
0.1 0.2 0.5 1 2 5 10
Favours cycled Favours culture-based
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Analysis 6.2. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
2 Mean 70-week change in FEV1 % predicted.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 2 Mean 70-week change in FEV1 % predicted
Study or subgroup Cycled Culture-based
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 73 0.77 (12.65) 70 -1.61 (14.01) 2.38 [ -2.00, 6.76 ]
-10 -5 0 5 10
Favours culture-based Favours cycled
Analysis 6.3. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
3 Mean 70-week change in weight from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 3 Mean 70-week change in weight from baseline
Study or subgroup Cycled Culture-based
Mean
Difference
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 4 (2.7) 152 3.9 (2.4) 0.10 [ -0.47, 0.67 ]
-1 -0.5 0 0.5 1
Favours culture-based Favours cycled
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Analysis 6.4. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
4 Mean 70-week change in height from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 4 Mean 70-week change in height from baseline
Study or subgroup Cycled Culture-based
Mean
Difference
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 9.2 (2.8) 152 9.4 (3.1) -0.20 [ -0.86, 0.46 ]
-1 -0.5 0 0.5 1
Favours culture-based Favours cycled
Analysis 6.5. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
5 Time to severe pulmonary exacerbation.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 5 Time to severe pulmonary exacerbation
Study or subgroup Cycled Culture-based log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 152 -0.0513 (0.286) 0.95 [ 0.54, 1.66 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
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Analysis 6.6. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
6 Participants with one or more severe pulmonary exacerbations.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 6 Participants with one or more severe pulmonary exacerbations
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 24/152 26/152 0.91 [ 0.50, 1.67 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
Analysis 6.7. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
7 Time to pulmonary exacerbation (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 7 Time to pulmonary exacerbation (any severity)
Study or subgroup Cycled Culture-based log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 152 -0.223 (0.135) 0.80 [ 0.61, 1.04 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
72Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.8. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
8 Participants with one or more pulmonary exacerbations (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 8 Participants with one or more pulmonary exacerbations (any severity)
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 70/152 81/152 0.75 [ 0.48, 1.17 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
Analysis 6.9. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
9 Participants with new isolates of Stenotrophomonas maltophilia.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 9 Participants with new isolates of Stenotrophomonas maltophilia
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 29/138 26/141 1.18 [ 0.65, 2.12 ]
0.1 0.2 0.5 1 2 5 10
Favours cycled Favours culture-based
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Analysis 6.10. Comparison 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin, Outcome
10 Participants with one or more serious adverse event.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 6 Cycled inhaled tobramycin versus culture-based inhaled tobramycin
Outcome: 10 Participants with one or more serious adverse event
Study or subgroup Cycled Culture-based Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 39/152 44/152 0.85 [ 0.51, 1.40 ]
0.5 0.7 1 1.5 2
Favours cycled Favours culture-based
Analysis 7.1. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 1 Participants with one or more isolates of P. aeruginosa from respiratory tract.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 1 Participants with one or more isolates of P. aeruginosa from respiratory tract
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 49/146 55/152 0.89 [ 0.55, 1.44 ]
0.1 0.2 0.5 1 2 5 10
Favours ciprofloxacin Favours placebo
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Analysis 7.2. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 2 Mean 70-week change in FEV1 % predicted.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 2 Mean 70-week change in FEV1 % predicted
Study or subgroup Ciprofloxacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 67 1.17 (13.56) 76 -1.85 (12.89) 3.02 [ -1.33, 7.37 ]
-10 -5 0 5 10
Favours placebo Favours ciprofloxacin
Analysis 7.3. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 3 Mean 70-week change in weight from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 3 Mean 70-week change in weight from baseline
Study or subgroup Ciprofloxacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 3.8 (2.5) 152 4.1 (2.7) -0.30 [ -0.88, 0.28 ]
-2 -1 0 1 2
Favours placebo Favours ciprofloxacin
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Analysis 7.4. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 4 Mean 70-week change in height from baseline.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 4 Mean 70-week change in height from baseline
Study or subgroup Ciprofloxacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 9.2 (2.8) 152 9.4 (3.1) -0.20 [ -0.86, 0.46 ]
-1 -0.5 0 0.5 1
Favours placebo Favours ciprofloxacin
Analysis 7.5. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 5 Time to severe pulmonary exacerbation.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 5 Time to severe pulmonary exacerbation
Study or subgroup Ciprofloxacin Placebo log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 152 0 0.3716 (0.439) 1.45 [ 0.61, 3.43 ]
0.02 0.1 1 10 50
Favours ciprofloxacin Favours placebo
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Analysis 7.6. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 6 Participants with one or more severe pulmonary exacerbations.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 6 Participants with one or more severe pulmonary exacerbations
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 29/152 21/152 1.47 [ 0.80, 2.72 ]
0.2 0.5 1 2 5
Favours ciprofloxacin Favours placebo
Analysis 7.7. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 7 Time to pulmonary exacerbation (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 7 Time to pulmonary exacerbation (any severity)
Study or subgroup Ciprofloxacin Placebo log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 83 68 0.2546 (0.214) 1.29 [ 0.85, 1.96 ]
0.1 0.2 0.5 1 2 5 10
Favours ciprofloxacin Favours placebo
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Analysis 7.8. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 8 Participants with one of more pulmonary exacerbation (any severity).
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 8 Participants with one of more pulmonary exacerbation (any severity)
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 83/152 68/152 1.49 [ 0.95, 2.33 ]
0.5 0.7 1 1.5 2
Favours ciprofloxacin Favours placebo
Analysis 7.9. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 9 Participants with new isolates of Stenotrophomonas maltophilia.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 9 Participants with new isolates of Stenotrophomonas maltophilia
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 29/137 26/142 1.20 [ 0.66, 2.16 ]
0.5 0.7 1 1.5 2
Favours ciprofloxacin Favours placebo
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Analysis 7.10. Comparison 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled
tobramycin, Outcome 10 Participants with one or more serious adverse event.
Review: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Comparison: 7 Ciprofloxacin versus placebo added to cycled and culture-based inhaled tobramycin
Outcome: 10 Participants with one or more serious adverse event
Study or subgroup Ciprofloxacin Placebo Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Treggiari 2011 48/152 35/152 1.54 [ 0.93, 2.57 ]
0.2 0.5 1 2 5
Favours ciprofloxacin Favours placebo
WH A T ’ S N E W
Last assessed as up-to-date: 29 October 2014.
Date Event Description
29 October 2014 New search has been performed A search of the Group’s CF Register identified 117 ref-
erences for possible inclusion in the review
Three references have been added to an already included
trial (Proesmans 2013). One trial, known as the ELITE
trial, has been moved from ’Ongoing studies’ to ’In-
cluded studies’ and the reference to the full publication
added; this trial has provided a comparison of duration
of intervention not previously available for inclusion
(Ratjen 2010). A further trial also previously listed as
ongoing with the study ID Ramsey 2005 (also known
as the EPIC trial) has been included with 11 new refer-
ences (Treggiari 2011). One new trial, with nine refer-
ences has been included (Taccetti 2012).
A total of 22 new trials (97 references) have been ex-
cluded: one reference each (Alothman2005;Goss 2009;
Prayle 2013; Postnikov 2007; Wainwright 2011b);
two references each (Alothman 2002; Kenny 2009;
Mainz 2014; Schelstraete 2010; Tramper-Stranders
2009); three references each (Coates 2011; Geller
2007; Mazurek 2012; Rietschel 2009); four references
each (Retsch-Bogart 2008; Trapnell 2012); five refer-
ences each (Clancy 2013; Konstan 2010); six refer-
ences each (Oermann 2009; Schuster 2013); 10 refer-
79Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
ences (Retsch-Bogart 2009); and 32 references (Ramsey
1999).
Two trials previously listed as ’Awaiting classification’
have now been excluded (Latzin 2008; Lenoir 2007).
One additional reference has been added to a previously
excluded study (Wainwright 2011a)
The full paper to an abstract already listed as ’Awaiting
Classification’ has now been published and added to the
existing study ID while we await clarification regarding
participants from the authors (Noah 2010).
One new trial (with a single reference) has been added
to ’Ongoing studies’ (TORPEDO Trial).
There have been three post hoc changes to the review at
this update:
• we now include participants who have received
treatment within six months of the first isolation of P.
aeruginosa (previously not more than two months);
• we now allow trials where all patients receive
some eradication therapy before randomisation which
reflects current recommended ’standard of care’ and
consequent trial design;
• we have added cost as an outcome measure, as
cost-effectiveness has become increasingly important
in CF care.
29 October 2014 New citation required but conclusions have not
changed
This review has been updated, but the conclusions re-
main the same
H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 1, 2006
Date Event Description
10 June 2009 New search has been performed A new search of the Group’s CF Register identified 14
new references
We have included one new study with one refer-
ence (Proesmans 2013) and excluded two new studies
with three new references (Postnikov 2000; Steinkamp
2007). Three studies with a total of five references are
listed as ’Awaiting classification’ until we are able to
obtain further details (Latzin 2008a; Lenoir 2007a;
Noah 2007)
We have added five references to the two ongoing stud-
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(Continued)
ies: one reference to Ramsey 2005a and four references
to Ratjen 2006a
10 June 2009 New citation required but conclusions have not
changed
From the 2009 update of this review, the lead author
Dr Damian Wood has stepped down and is no longer
involved in the review. The new lead author is Dr
Simon Langton Hewer
12 November 2008 Amended Converted to new review format.
13 November 2007 Amended The review authors have addressed some comments
from the CFGD Group’s medical statistician within
this update
13 November 2007 New search has been performed The search identified four new trials; two of which
have been excluded (Gibson 2007; Griese 2002); and
two of which are still ongoing (Ramsey 2005a; Ratjen
2006a)
15 November 2006 Feedback has been incorporated The review now contains the response from the au-
thors to feedback regarding the necessity of further tri-
als received through The Cochrane Library Feedback
system.
C O N T R I B U T I O N S O F A U T H O R S
Damian Wood wrote the first draft of the review and both Damian Wood and Alan Smyth edited it to produce the final original review
version. Both Damian Wood and Alan Smyth have worked on updated versions of the review up until 2007. As from Issue 2, 2009 the
new lead author is Simon Langton Hewer. The most recent version of the review was jointly written by Simon Langton-Hewer and
Alan Smyth.
Simon Langton Hewer acts as guarantor of the review.
D E C L A R A T I O N S O F I N T E R E S T
Dr Langton Hewer is the lead investigator on the ongoing trial Torpedo-CF: Trial of Optimal Therapy for Pseudomonas Eradication
in Cystic Fibrosis.
Prof Smyth has received financial support from Forest Laboratories and Gilead (both companies market a nebulised antibiotic) and
from MPEX Pharma (nebulised antibiotic in development).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2014
The inclusion criteria have been changed to include participants who have received study treatment within six months of the first
isolation of P. aeruginosa (previously not more than two months). This is to reflect differences in clinical practice between Europe and
North America and to allow trials from earlier decades (where early treatment of P. aeruginosa was not established clinical practice) to
be included. A large trial (306 participants), published in 2011, is therefore now eligible for inclusion (Treggiari 2011). However, it is
possible that, where infection has been present for as long as six months, it may have become more difficult to eradicate.
In recent years 28 days of inhaled tobramycin has been recommended as ’standard of care’ for eradication of P. aeruginosa in guidelines
(Döring 2012). This has been reflected in trial design, where investigators have designed their trials to ensure that all patients receive an
initial 28-day course of inhaled tobramycin before randomisation to the next stage of therapy. We have therefore altered our eligibility
criteria to allow trials where all patients receive some eradication therapy before randomisation (Treggiari 2011).
We have added cost as an outcome measure, as cost-effectiveness has become increasingly important in CF care. None of the trials
included to date have reported this outcome but future trials may do so.
2009
After new lead reviewer re-assessed the review, the section ’Objectives’ was expanded to include the sentence:
’To investigate whether there is evidence of superiority or improved cost-effectiveness between antibiotic strategies.’
Currently, we have included both P. aeruginosa free and P. aeruginosa naive patients according to the definition by Lee (Lee 2003). At
the update in 2009 we have added plans to analyse these subgroups separately if sufficient data become available from included studies
in the future.
2005
Two clinically relevant additional outcomes were added at review stage to the ones we had originally listed:
1. Time to chronic infection (defined as the presence of P. aeruginosa in each monthly sputum sample for six consecutive months or
the presence of precipitating antibodies to P. aeruginosa or both)
2. Clinical and radiological scores
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Pseudomonas aeruginosa; Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents [administration & dosage;
∗therapeutic use]; Ciprofloxacin [administration &dosage; therapeutic use]; Colistin [administration & dosage; therapeutic use]; Cystic
Fibrosis [∗complications; microbiology]; Pseudomonas Infections [∗drug therapy]; Randomized Controlled Trials as Topic; Tobramycin
[administration & dosage; therapeutic use]
MeSH check words
Adult; Child; Humans
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